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ABSTRACT 
Katharine Joy Liang: AAV-Nrf2 mediated rescue of oxidative stress in mouse models 
(Under the direction of R. Jude Samulski) 
 
Oxidative stress is implicated in many diseases in a variety of different organ systems. 
While specific antioxidant genes are known to contribute to the regulation and breakdown of 
reactive free radicals, harnessing their power to combat oxidative stress remains elusive due to 
the need for a coordinated regiment of several antioxidant enzymes acting together to produce 
therapeutic effect. Many of these enzymes share a common promoter element, the Antioxidant 
Response Element (ARE). Chemical activators of the ARE have shown promise as therapeutic 
effectors due to their ability to upregulate coordinated expression of a panel of antioxidant 
genes, but this strategy is lacking in cases where long-term oxidative stress is present. 
Nrf2 is a transcription factor that drives antioxidant gene expression. We hypothesized 
that Nrf2 overexpression can be used as therapy by which antioxidant genes facilitate redox 
homeostasis. Due to its safety profile, low immunogenicity, and ability to facilitate long term 
gene expression, Adeno-associated virus (AAV) was used to deliver persistent Nrf2 
overexpression in mice. In this dissertation, I describe two studies in which we applied this 
Nrf2-based gene therapy strategy to rescue mouse models from oxidative stress-induced 
disease. First, AAV-Nrf2 was delivered systemically via tail vein injection to mediate Nrf2 
overexpression primarily in the liver. AAV-Nrf2 gene replacement in Nrf2-/- mice, as well as 
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overexpression in wild-type mice, was able to prevent mortality from acetaminophen-induced 
hepatotoxicity. Secondary outcomes of liver enzymes and liver histopathology were also 
characterized. Secondly, AAV-Nrf2 was injected intravitreally to mediate Nrf2 expression in the 
retina. AAV-Nrf2 overexpression successfully rescued mice from light-induced retinal 
degeneration, a model that recapitulates many features of age-related macular degeneration in 
humans. Outcome measures included retinal thickness measured using in vivo optical 
coherence tomography imaging and retinal function as measured by electroretinography. 
This work demonstrates that AAV-Nrf2 has viable therapeutic potential to combat 
oxidative stress across multiple organ systems. The long term persistence of rescue, along with 
the time course of loss and regaining of function following insult seen in the retinal model in 
particular, supports a potential role for Nrf2 in regeneration and tissue repair in addition to its 
role in combating acute oxidative insults. 
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PREFACE 
 
 The following is a compilation of several primary author publications. Chapters one and 
four are book chapters that have been accepted for publication. In addition to these chapters, 
my dissertation work has focused on evaluating the therapeutic potential of AAV-mediated 
delivery of Nrf2 in several different systems. Chapter two summarizes my findings in vitro and 
in a mouse liver toxicity model. Chapter three summarizes my findings in a mouse model of 
retinal degeneration and is a draft of a primary author manuscript that will be submitted 
shortly. Together, all these works comprise my dissertation. 
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CHAPTER 1: Viral vectors for gene delivery1 
 
1.1 Introduction 
Wild-type viruses naturally infect cells and deliver their genetic material to be replicated 
by host cellular machinery. Their biological life cycle lends itself naturally to serve as a vehicle 
for gene therapy applications. Over the past several decades, considerable effort in the field has 
been made to engineer an array of recombinant viral vectors for gene therapy applications. 
Compared to nonviral delivery methods reviewed in previous chapters, viral vectors have led 
the pack in gene therapy clinical trials, with 1354 trials accounting for 67% of all those reported 
at the time of this writing (Figure 1.1) [1]. In this chapter we will review the development of 
three main families of viral vectors most commonly used in gene therapy applications: 
retroviruses, adenoviruses, and adeno-associated viruses (AAV). All have shown some measures 
of clinical success as gene delivery vectors, but as we will outline in this chapter, each vector 
has tradeoffs that lend themselves well to specific niches in the gene therapy field. 
1.2 Retroviruses 
Retroviruses are single-stranded RNA viruses that are characterized by their ability to 
reverse transcribe their genome and integrate it into that of the target cell (Table 1.1). The 
                                                     
1 Reproduced from Advances and Challenges in Delivery of Nucleic Acid Therapeutics. London: Future Science, 
accepted for publication 5 March 2014. Ebook. 
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simple retroviral genome contains gag, pro, pol, and env genes; complex retroviruses also 
contain additional regulatory and accessory genes. Gag encodes major structural proteins 
including the matrix protein, capsid, and nucleocapsid; pro and pol encode protease, reverse 
transcriptase, and integrase proteins; and env encodes envelope proteins. Following retroviral 
infection, reverse transcription of the viral RNA genome flanked by short terminal repeats, 
produces a DNA product flanked by long terminal repeats (LTRs, Figure 1.2) [2]. Reverse 
transcription is followed by integration into the host genome, after which transcription of the 
viral genome takes place alongside cellular genes. 
Retroviral vectors paved the way for clinical gene therapy in 1990 when a retroviral 
vector was used to deliver the first therapeutic gene into humans [3]. Retroviral vectors have 
been valued for their ability to mediate robust and persistent gene expression. Their ability to 
integrate into the host genome also makes them an ideal gene delivery vector for stem cell 
therapy, as once a cell is infected and the viral DNA is integrated into the host genome, all 
daughter cells will contain copies of the virally-delivered transgene. However, their 
development as clinical gene therapy vectors has been hampered by biosafety concerns 
exceeding those of other vectors (Figure 1.3). Because replication-competent retroviruses 
(RCRs) were found to cause oncogenesis due to insertional mutagenesis [4], considerable effort 
was made to engineer replication-deficient retroviral vectors by separating the transgene 
cassette from wild-type genes (Table 1.2) [5, 6]. Theoretically, separating genes onto two 
plasmids requires a minimum of one, three plasmids require two, and four plasmids require 
three recombination events for RCR generation. Additional elimination of accessory viral 
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proteins made these recombination events less likely to occur. Because first-generation vectors 
were more permissive to recombination events, often resulting in RCR contamination during 
vector production, only second and third generation retroviral vectors have been used in 
clinical trials. In this section we will discuss the development of two subfamilies of retroviral 
vectors most widely used in gene therapy applications: gamma-retroviruses and lentiviruses. 
1.2.1 Gamma-retroviral vectors 
Early development of retroviral vectors focused on gamma-retroviral vectors, in 
particular murine leukemia virus (MLV)-based vectors. Because the MLV nucleocapsid complex 
does not contain a nuclear localization signal, the virus can only infect actively dividing cells [7].  
Gene therapy applications capitalized on this feature by utilizing MLV-based vectors in adoptive 
cell transfer approaches to genetically engineer hematopoietic stem cells ex vivo and 
autotransplant corrected cells back into the patient for diseases such as cancer and 
hematopoietic deficiencies. 
Gamma-retroviral vectors first demonstrated the oncogenic risk of RCRs [4], and 
replication-defective vectors were engineered by various strategies to reduce risk of RCRs by 
recombination events during in vitro vector production (Table 1.2). However, despite the use of 
replication-defective MLV-based vectors, oncogenesis occurred in several patients during early 
gene therapy clinical trials (For a review of gene therapy adoptive cell transfer applications, 
refer to CHAPTER 4).  This has later been attributed to two primary factors (Figure 1.3): 
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1. Skewed integration. MLV integration strongly favors transcription start sites, increasing 
the likelihood of insertional mutagenesis activating proto-oncogenes that are silenced 
during hematopoiesis [8, 9]. 
2. Strong promoter/weak polyA. The strong promoter activity but weak polyadenylation 
signal provided by the MLV LTRs results in a possible LTR-induced activation of host 
genes downstream of the insertion site [10, 11]. 
The risk of MLV-induced oncogenesis has limited their use in certain gene therapy applications, 
and led to the development of lentivirus, which has been demonstrated to be a safer and more 
versatile gene delivery vector. 
1.2.2 Lentiviruses 
Lentiviruses are complex retroviruses containing regulatory and accessory genes, one of 
which encodes a nuclear localization signal that allows infection of non-dividing cells, in 
addition to dividing cells. Unlike gamma-retroviral vectors, lentiviral vectors are not associated 
with skewed integration sites that promote oncogenesis [12], but instead favor integration 
within actively transcribed genes [8]. Nevertheless, because most lentiviral vectors are derived 
from HIV, generation of replication-competent lentiviruses (RCLs) and vector mobilization are of 
great concern (Figure 1.3) [13]. Developments to further elevate the safety profile of lentiviral 
vectors have addressed decreasing risks of RCLs, vector mobilization, and insertional 
mutagenesis (Table 1.2) [14]. First, second, and third generation lentiviral vectors were 
developed by placing wild-type viral genes and the vector expression cassette on separate 
vector production plasmids, eventually eliminating all non-essential viral genes. The segregation 
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of the vector expression cassette, packaging genes, and envelope genes on separate plasmids 
greatly reduced the risk of RCLs [14].  
1.2.3 Self-inactivating vectors 
Another strategy to further elevate the safety profile of retroviral vectors was the 
creation of self-inactivating (SIN) vectors. SIN vectors have been explored using both gamma-
retroviral and lentiviral-derived vectors, and were created by deleting the retroviral U3 
enhancer-promoter regions, resulting in defective LTRs [15]. Instead of relying on LTR promoter 
activity, SIN vectors place transgene expression under the control of an exogenous promoter 
inserted just internal to the defective 5’ LTR, thus preventing the packaging signal from being 
expressed [10]. Not only do self-inactivating vectors decrease the risk of RCRs and vector 
mobilization, they also decrease the risk of insertional mutagenesis by preventing strong LTR 
promoter/enhancer readthrough from interfering with target cell genomic promoter/enhancer 
activity (Figure 1.3). 
1.2.4 Looking forward: strategies to limit problems associated with gene integration 
While retroviral-mediated gene delivery results in strong and persistent gene 
expression, integration into the host chromosome does lead toward epigenetic silencing over 
time. Several methods to optimize long-term expression and minimize transgene silencing are 
currently being developed, including insulators and scaffold/matrix attachment regions 
(S/MARs), locus control regions, and ubiquitous chromatin opening elements. These elements 
may also influence risks of insertional mutagenesis [16, 17]. 
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Insertional mutagenesis is a safety issue that has been pursued, but is still a real concern 
even in clinical-grade lentiviral vectors used today. While risks of oncogenesis are decreased 
with lentiviral vectors compared to gamma-retroviral vectors, insertional mutagenesis can still 
occur and result in disruption of important cellular processes. The development of integration-
deficient lentiviruses (IDLV) to deliver genes via episomes has been explored, reviewed 
elsewhere [18]. However, unlike integrated genes, episomes are not passed on to both 
daughter cells during replication, making IDLV unsuited for gene delivery to actively dividing 
cells until IDLVs can be engineered to deliver replicating episomes [18]. In the advent of safer, 
more versatile AAV-driven gene therapy technology, lentivirus will likely continue to take a 
backseat when it comes to gene delivery to non-replicating cells, except perhaps in cases where 
the small AAV packaging size cannot be overcome.  
Indeed current clinical gene therapy using lentivirus continues to focus on applications 
in actively dividing cells. Quality control measures have necessarily improved; gene-corrected 
stem cells are now screened for insertional mutagenesis before autotransplantation. Another 
major step towards decreasing this risk involves modifying the viral integrase with a polydactyl 
zinc finger, or replacing the integrase with a zinc finger fused to a nuclease, to promote 
preferential site-specific integration [19]. Zinc fingers combined with increased quality control 
are steps in the right direction, but until we have complete control over lentiviral integration, 
integration risks are still very real. The challenges that lie ahead must move toward technology 
that provides complete control over lentiviral integration into specific sites in the host genome. 
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1.3 Adenoviral vectors 
 Adenoviruses are double-stranded DNA viruses that do not integrate, and can infect 
both dividing and non-dividing cells (Table 1.1). Following adenovirus infection, the E1A 
transcription unit initiates transcription, producing “intermediate early” E1A proteins that 
induce transcription of “delayed early” E1B, E2, E3, and E4 genes. E1 and E3 proteins contain 
promoter activity and modulate host antiviral response to infection [2, 20]. E2 proteins are 
directly involved in viral genome replication, whereas E4 proteins mediate a wide variety of 
functions, including transcription and translation, mRNA nuclear export and RNA splicing, as 
well as apoptosis. Together, these early/intermediate proteins coordinate viral replication 
around 7 hours post-infection. Once major-late proteins are expressed, viral particle assembly 
begins at 20-24 hours, and cell lysis occurs between days 2-6 [2]. For an in-depth review of 
adenovirus biology, refer to [2]. 
 Adenovirus continues to lead the pack in gene therapy clinical trials, with 476 trials 
accounting for 23.5% of all clinical trials to date (Figure 1.1), most using variations on 
adenovirus serotype2 5. Because adenovirus is highly immunogenic and cytolytic, development 
of adenoviral vectors over the years has accordingly focused on two major aspects of viral 
vector biosafety (Figure 1.3): 
1. Immune response. Because adenovirus is a common human pathogen, much of the 
human population has preexisting adenoviral neutralizing antibodies. Both humoral and 
                                                     
2 Serotype refers to variations in viral surface antigens within a single viral species that result in different 
immunogenicity profiles. 
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cell-mediated immunity commonly leads to adenoviral clearance and loss of therapeutic 
gene expression. Wild-type viral proteins, accompanied by a cytotoxic T lymphocyte 
(CTL) response, can also have a toxic effect on the transduced cells themselves, which 
may or may not be desired depending on the application. Finally, if the CTL response 
gets out of control, this can have serious, even fatal effects in vivo [21]. 
2. Viral replication. The earliest push in the development of Adenovirus as a gene delivery 
vector was deleting the proteins responsible for viral replication, creating replication-
deficient adenoviral vectors. Adenovirus is cytotoxic and highly immunogenic, so limiting 
RCVs and vector mobilization is key to avoiding a destructive immune response from 
uncontrolled proliferation of a cytotoxic virus [22-24]. 
1.3.1 First, second, and third generation adenoviral vectors 
Over several generations of vector development, gradual deletion of wild-type 
adenoviral genes has been aimed at addressing biosafety, as well as serving to increase vector 
packaging capacity (Table 1.3). First generation adenoviruses are replication-deficient, capable 
of only one round of replication. Transduction with first generation adenoviral vectors results in 
the production of a single genome containing only the transgene cassette, Ad packaging signals, 
and Ad inverted terminal repeats (ITRs)3 [20]. Though limiting replication increases the safety 
profile of these vectors, because they still contain viral proteins, immunogenicity is still a 
problem. Second and third generation adenoviruses further decreased the risk of development 
                                                     
3 Inverted terminal repeats (ITRs) are short self-complementary sequences required for packaging that create 
double-stranded termini in single-stranded DNA. ITRs often contain promoter activity and serve as origins of 
replication. 
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of RCVs and immunogenicity. Third generation constructs are devoid of all wild-type adenoviral 
genes except ITRs and a packaging signal, instead relying on a helper adenovirus to carry wild-
type coding regions [21]. Third generation adenoviruses go by many names, including gutless 
adenovirus, helper-dependent adenovirus, and high-capacity adenovirus. 
These recombinant adenoviral constructs have required development of special 
protocols for in vitro production. Cell lines expressing various combinations of viral proteins 
have been developed for production of first and second generation vectors, facilitating efficient 
large-scale production capacity. Most registered adenovirus gene therapy clinical trials to date 
have used first or second generation replication-deficient adenoviral vectors [25]. Third 
generation adenoviruses require coinfection with a helper adenovirus for production, and 
purifying therapeutic vectors from helper adenovirus is cumbersome. Therefore, there remains 
an inherent increased risk that third generation adenoviral preps are contaminated with 
replication-competent helper virus. While progress has been made to improve production 
protocols [26-28], inadequate large scale production efficiency for helper-dependent adenoviral 
vectors still limits their utility in large-scale clinical applications [23]. 
1.3.2 Looking forward: oncolytic adenoviral vectors 
Rather than taking steps to limit adenovirus pathogenicity, recent cancer gene therapy 
applications have exploited adenovirus cytotoxicity in oncolytic-based therapeutics. Not 
surprisingly, cancer is the most common application of adenoviral-based gene therapy to date 
[2]. In some cases, this cytotoxic effect is maximized by the use of replication-competent 
adenoviral vectors. In order to limit toxicity in noncancerous cells, replication-selective 
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adenoviral vectors have been developed that preferentially replicate in tumor cells [29]. The 
cytolytic activity of replicating adenovirus itself is often combined with suicide gene therapy 
strategies to maximize oncolysis (see CHAPTER 4). Several strategies have been explored for 
tumor-specific replication that involve mutant or deleted viral E1 proteins. One such widely 
studied adenoviral vector, ONYX-015, contains a deletion of one of the E1B proteins that binds 
and inactivates p53, theoretically increasing selectivity for replication in p53-deficient tumor 
cells [29]. Another one contains mutations in the E1A proteins responsible for driving quiescent 
cells into S phase, the mechanism by which adenovirus is able to replicate in non-dividing cells 
[22]. One of the most promising oncolytic vectors so far is ColoAd1, which contains deletions 
within E3 and E4, and is derived from parental capsids Ad3 and Ad11p by directed evolution 
[30]. ColoAd1 has shown preliminary success in clinical trials, with increased oncolytic activity 
compared to parental constructs, as well as Ad5, perhaps in part due to decreased cross-
reactivity of pre-existing neutralizing antibodies with this recombinant capsid serotype [31, 32]. 
Though these systems need further development to obtain absolute selectivity for malignant 
cells, oncolytic adenoviral systems have broad appeal and are currently being evaluated in 
several registered clinical trials [25]. 
1.4 Adeno-associated viral vectors 
Adeno-associated viruses (AAV) are part of the virus family Parvoviridae, genus 
Dependovirus, which comprise small, nonenveloped, single-stranded DNA viruses that require 
co-infection with a helper virus for replication (Table 1.1). AAV uses adenovirus most commonly 
as a helper virus, though use of herpesvirus has also been known [2]. In the absence of a helper 
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virus, AAV can still establish long-term latent infection by integrating into a well-studied 
location on human chromosome 19 [33] and existing episomally. Subsequent infection with a 
helper virus may be able to rescue the latent virus and induce replication. The AAV genome 
consists of Rep and Cap genes, flanked by ITRs. ITRs form hairpin structures and are necessary 
for viral packaging and second strand synthesis [34]. AAV are not associated with any 
pathogenesis, are not cytotoxic, and integration is not known to cause any detrimental effects. 
For an in-depth review of AAV biology, refer to [2]. 
 AAV remains the safest gene delivery vector in clinical applications to date. Current AAV 
production protocols use a triple transfection method, in which Ad helper genes, AAV rep and 
cap genes, and transgene cassettes are provided on separate plasmids to transduce cells for in 
vitro production [35]. The Ad helper plasmid only contains genes essential for AAV replication, 
and is unable to provide genes necessary for adenovirus production. The transgene cassette is 
the only one of the three that is flanked by ITRs, allowing selective packaging of the transgene 
construct but excluding both AAV and adenoviral rep proteins. Thus, infection with both wild-
type adenovirus and AAV would be necessary to mobilize a latent AAV infection [36]. 
1.4.1 Strategies for increasing transduction efficiency 
Because serious pathological effects have not been observed with AAV vectors, vector 
development has focused more on increasing transduction efficiency than biosafety. As 
discussed above, risks of replication-competent AAV and mobilization are low. Immunogenicity 
is a concern with AAV vectors; however immune response to AAV has rarely resulted in any 
measurable pathological effects. Rather, it is of concern because it limits long-term transgene 
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expression (Figure 1.3). Transient transgene expression and low transduction efficiency are 
issues that have guided the development of AAV as a gene delivery vector. Another drawback 
of AAV as a gene delivery vector is its small packaging capacity. The development of AAV as a 
gene delivery vector has resulted in numerous strategies for engineering AAV vectors that have 
addressed these concerns and can be used in a wide range of applications. An impeccable 
safety profile, and combined versatility for capsid and genome manipulation have propelled 
AAV to the forefront of viral gene delivery vectors (See CHAPTER 4 for a review of AAV clinical 
applications). 
1.4.2 Pseudotyping and transcapsidation 
Of the over 100 naturally-occurring serotypes that have been isolated, nine have been 
exploited for gene therapy to date (Table 1.4) [34]. Most clinical trials to date have used AAV2; 
however over half of the human population has preexisting neutralizing antibodies against the 
AAV2 capsid, limiting its clinical utility [37]. One potential solution is pseudotyping4 the well-
characterized AAV2 ITR-based vector cassette with other capsid serotypes [38], as 
seroprevalence of antibodies against some capsids is greater than others (Figure 1.4). It should 
be mentioned that almost all gene therapy applications continue to use the well-characterized 
AAV2 ITRs in vector cassettes. In addition to the benefit of decreased immunogenicity of 
different capsid serotypes, each capsid has a unique tropism for trafficking to different organ 
systems with varying affinity (Table 1.4). However, one caveat of this approach is that 
                                                     
4 Pseudotyping is a process in which a vector transgene flanked by ITRs from one serotype is packaged into a capsid 
of another serotype, creating a chimeric viral vector. 
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antibodies against some serotypes may have partial cross-reactivity with other serotypes [37]. 
Therefore, a logical extension of pseudotyping was transcapsidation5, in which capsids were 
engineered to contain capsid proteins derived from multiple serotypes, creating recombinant 
AAV vectors that may have decreased immunogenicity (Figure 1.4) [39]. 
Furthermore, AAV’s relatively simple capsid structure allows surface receptor motifs to 
be easily mutated, resulting in creation of capsid mutants with altered tropism without greatly 
changing the overall capsid structure. Developments over the last decade have taken 
pseudotyping and transcapsidation to the next level through directed evolution and rational 
design strategies of engineering recombinant chimeric AAV vectors. Directed evolution 
strategies most commonly involve the creation of a vector capsid library through DNA shuffling 
of AAV capsids, then selecting for specific tropism either in vitro [40, 41] or in vivo [42]. Rational 
design strategies utilize knowledge of AAV capsid biology to mutate small regions of the capsid 
[43], and have been effectively used to increase affinity for viral entry receptors [44] and evade 
immune response [45]. 
1.4.3 Self-complementary AAV 
Following viral entry, a second rate-limiting step for AAV transduction is second-strand 
synthesis, in which the single-stranded AAV genome must be converted into a double-stranded 
DNA molecule prior to transcription (Figure 1.4). The development of self-complementary (sc) 
transgene cassettes completely bypasses the second-strand synthesis step, allowing for 
                                                     
5 Transcapsidation refers to the use of a viral capsid containing proteins derived from multiple serotypes, creating 
recombinant viral vectors. 
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increased transduction efficiency. ScAAV constructs have the potential for faster expression 
onset following transduction, as well as higher and more widespread overall levels of 
expression, suggesting that second-strand synthesis is not only a kinetic bottleneck in AAV 
transduction, but also that some cells simply lack factors necessary for second-strand synthesis 
[46]. ScAAV constructs are made by reducing the size of the vector construct by half (~2.5kb), 
such that two vector constructs can be packaged as a dimer [47]. Although the resulting viral 
preps from this procedure contain a mixture of scAAV and ssAAV due to varying efficiency of 
scAAV packaging, even viral preps containing as low as 5% scAAV have seen significant 
increases in transduction efficiency [46]. The major limitation of scAAV is the reduction in 
packaging space by half of an already small virus. Indeed, small packaging size is one of the 
major limitations of AAV as a gene delivery vector to begin with, and several strategies to 
further optimize AAV vectors have been used to address this issue. 
1.4.4 Strategies for packaging large genes 
Although AAV packaging size can vary depending on capsid serotype [46], the packaging 
capacity of AAV is generally considered to be less than 5kb. This severely limits the transgene 
size that can be inserted into the vector cassette, particularly after accounting for the size of 
the ITRs, promoter, and polyA sequences. One strategy is the engineering of “mini” genes in 
which unnecessary elements within a large gene are deleted. This strategy has been effectively 
used to package functional mini versions of CFTR [48] and dystrophin [49] into AAV. Mini 
promoter and regulatory elements have also been successfully implemented in many 
applications, most notably in recent clinical trials for hemophilia B, in which a mini-FIX cassette 
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was engineered to accommodate scAAV packaging [50] (see CHAPTER 4 for a review of gene 
therapy clinical trials for hemophilia and cystic fibrosis). Split genomes are another possibility, 
where transgene cassettes larger than 5kb are naturally truncated and packaged separately into 
AAV capsids, and repaired to full length via homologous recombination or nonhomologous end 
joining following viral entry into the host cell [51]. Although in a naturally occurring fashion this 
process is fairly inefficient, engineering vector cassettes with greater recombination 
permissibility could increase its feasibility. 
1.4.5 Looking forward: transcapsidation leads the way 
AAV’s advantages of safety and versatility make it a prime candidate for many gene 
therapy applications looking forward. In particular its flexible production scheme that allows 
ready pseudotyping of an array of natural and engineered capsid serotypes make AAV 
customizable to a variety of different applications makes AAVs a promising choice. Future 
developments to elevate the efficacy and applicability of AAV-mediated gene delivery will look 
to engineer and even more capsid mutants that further enhance transduction efficiency. It is 
becoming increasingly clear that while cellular entry is important, intracellular viral trafficking is 
an even greater rate-limiting process, reviewed in depth elsewhere [52]. Vectors that evade 
proteosomal degradation have shown much promise both in vitro and in vivo [53]. Optimizing 
AAV capsids for efficient intracellular trafficking, such as increasing efficiency of endosomal 
escape and nuclear entry, will play a large role in guiding development of future AAV vectors. 
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1.5 Non-traditional viral vectors 
 In addition to the three main groups of viral vectors discussed above, several non-
traditional viral vectors are gaining momentum in gene therapy applications and are currently 
in phase I clinical trials for cancer. Among these viruses developed for use as oncolytic vectors 
are oncolytic herpes simplex virus (HSV), poliovirus, measles virus, and autonomous parvovirus. 
HSV has the advantage of an extremely large packaging size, and effective killing in dividing 
cells. Their oncolytic activity has been enhanced by engineering of HSV mutants that enhance 
antigen presentation and viral replication. Poliovirus has the advantage of increased tropism for 
neurons, making it a good candidate for treatment of gliomas, and mutants have been created 
that attenuate its activity in healthy neurons. Measles virus contains a pro-apoptotic protein 
and recombinant vectors have been engineered to have increased tropism for gliomas. Unlike 
AAV, autonomous parvovirus can replicate independently of a helper virus, and several strains 
have shown promise as an oncolytic vectors [54].  
1.6 Concluding remarks 
 Viral vectors remain the most clinically effective vehicles for gene delivery. Retroviral 
vectors have shown great success for ex vivo gene therapy of hematopoietic stem cells and 
adoptive cell transfer. Adenoviral vectors pioneered the way for gene replacement therapy, but 
because of their cytolytic nature, are best suited for cancer gene therapy. AAV vectors show 
great promise for in vivo gene therapy of nonmalignant diseases. Future developments of viral 
vectors will focus on applying our knowledge of viral biology to optimize transduction efficacy 
and specificity while maintaining biosafety for clinical applications. 
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1.7 Figures and Tables 
 
Figure 1.1. Adenoviruses and retroviruses lead the way.  
In this illustration of viral delivery vector distribution in current clinical trials, numbers account 
for gene therapy clinical trials approved/initiated between 1989-2013. Reproduced with 
permission from [1] © Wiley 2013). 
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Figure 1.2. Long terminal repeats are regulatory sequences, consisting of U3 and U5 
promoter-enhancer sequences and short terminal repeats that flank the viral genome. 
LTRs (gray) are produced by duplication of U3 and U5 regions just inside the short terminal 
repeats (R) during reverse transcription (RT) and mediate integration and transcription of the 
viral genome. Reproduced with permission from [21] © Wolters Kluwer 2013. 
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Figure 1.3. Biosafety concerns limit the clinical utility of viral vectors. 
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Figure 1.4. Strategies for optimizing AAV transduction efficiency. 
1) Viral capsid. Different organ systems and cell types express different viral entry receptors. 
The capsid can be altered to change affinity for particular cell surface receptors. Altering the 
viral capsid can also be a strategy for decreasing immunogenicity.  2) Second-strand synthesis. 
The use of self-complementary transgene cassettes allows AAV packaging of double-stranded 
DNA genomes, thereby bypassing second strand synthesis.  3) Promoter. Choice of promoter in 
the vector cassette can greatly alter strength and specificity of gene expression. 
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Table 1.1. Comparison of Major Viral Gene Delivery Vectors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Viral vector 
(images to scale) 
Retrovirus 
 
 
Adenovirus 
 
 
AAV 
 
 
 
 
Diameter (nm) 100 90 25 
Genomic material ssRNA dsDNA ssDNA 
Genome size 7-12 kb 36 kb 4.7 kb 
Packaging capacity 7-12 kb 14 kb (2nd generation) 
36 kb (3rd generation) 
4.7 kb (ss) 
2.5 kb (sc) 
Infect MLV – dividing only 
Lentivirus – dividing and 
non-dividing 
Dividing and non-dividing 
cells 
 
Gene expression Quick onset 
Long-term 
Transient Slow onset 
Long-term 
Integrating? Yes Rare Chromosome 19 only 
Cytolytic? No Yes No 
Biggest drawbacks Insertional mutagenesis 
Vector mobilization 
CTL response resulting in 
transient gene expression 
and cytokine storms 
Immune response 
Most promising clinical 
application 
Hematopoietic stem cells Cancer Monogenic diseases 
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Table 1.2. First, second, and third generation replication-defective retroviral vectors 
 
 
Table 1.3. First, second, and third generation adenoviral vectors 
 
 
 
 
 
Generation MLV Lentivirus 
1 Two separate plasmids: 
1. Vector plasmid retains LTRs, psi 
packaging sequence, and transgene 
2. Producer cell line provides all wild-
type MLV genes except psi packaging 
sequence 
Three separate plasmids: 
1. Vector plasmid for the transgene 
2. Packaging plasmid for wild-type 
lentiviral genes 
3. Envelope plasmid 
2 Two separate plasmids as above, except 
producer cell line provides provides all wild-
type genes except psi and 3’LTR 
Three separate plasmids as above, plus deletion 
of lentiviral accessory genes except tat and rev 
3 Three separate plasmids, all engineered to have 
reduced homology to discourage 
recombination: 
1. Vector plasmid retains LTRs, psi 
packaging sequence, and transgene 
2. Producer cell line provides provides all 
wild-type MLV genes except psi, 3’LTR, 
and env 
3. Envelope plasmid containing env 
Four separate plasmids: three as above, but 
segregation of rev on a fourth plasmid; 
elimination of tat 
Generation Features 
1 Deletion of viral E1 and/or E3 genes; insertion of exogenous promoter 
2 Deletion of viral E2 and/or E4 genes 
3 Deletion of all wild-type adenoviral genes except ITRs and a packaging signal 
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Table 1.4. Summary of adeno-associated virus serotypes6 
 
 
 
 
 
 
 
                                                     
6 Reproduced with permission from 34. Xiao, P.J., T.B. Lentz, and R.J. Samulski, Recombinant adeno-associated 
virus: clinical application and development as a gene-therapy vector. Ther Deliv, 2012. 3(7): p. 835-56. 
Serotype Origins Primary receptors Tissue tropism Clinical trials 
AAV1 Laboratory cell 
culture[55] 
N-linked SA[56] Muscle[57], lung[58], 
pancreas[59], CNS[60], 
eye[61]  
AAT[62], Lipoprotein Lipase 
Deficiency[63], muscular 
diseases[64], heart 
failure[65], inflammatory 
arthritis[66] 
AAV2 Laboratory cell 
culture [55] 
HSPG[67] Muscle[68], liver[69], 
kidney[70], CNS[71], 
eye[61] 
Most AAV-based trials 
AAV3 Laboratory cell 
culture [55, 72] 
HSPG[73] Muscle[74]  
AAV4 Laboratory cell 
culture [75] 
O-linked SA [76] Lung[77], CNS[78], Eye[79]  
AAV5 Human[80] N-linked SA [76] Muscle[74], lung[58], CNS 
and eye [81] 
Muscular diseases[82] 
AAV6 Laboratory cell 
culture [83] 
N-linked SA [44, 
56] 
Muscle[84], heart[85], 
lung[86],  
CF and heart failure[82] 
AAV7 Rhesus 
monkey[87] 
N/A Muscle[87], lung, eye[88], 
CNS[89] 
 
AAV8 Rhesus monkey 
[87] 
N/A Muscle[87, 90], heart[90], 
liver[87], pancreas[59], 
CNS[89], eye[88] 
Hemophilia B[50] 
AAV9 Human [91] N-linked 
galactose [92, 93] 
Muscle[94], heart[95], 
lung[91], liver[91], 
kidney[96], pancreas[95], 
CNS[97], eye[96] 
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CHAPTER 2: AAV-mediated delivery of Nrf2 in vitro and in vivo7 
2.1 Nrf2 signaling and expression 
 Nrf2 is a transcription factor that binds the Antioxidant Response Element (ARE), acting 
as a master regulator driving downstream antioxidant gene expression (Figure 2.1). Under 
normal homeostatic conditions, Nrf2 is bound to a Keap1 homodimer that sequesters Nrf2 in 
the cytoplasm via high affinity ETGE and low affinity DLG binding motifs [98]. The Keap1 
homodimer constitutively ubiquitinates and targets Nrf2 to the proteasome. Upon exposure to 
oxidative stress, modifications of reactive cysteine residues in Keap1 result in a change in 
conformation that likely releases the Nrf2 low affinity DLG-mediated binding. This 
conformational change blocks ubiquitination and proteasomal targeting, resulting in Nrf2 
nuclear accumulation and transcriptional activation. 
Nrf2 is expressed ubiquitously in many organ systems including the human and mouse 
liver and retina [99-102]. Nrf2-/- mice develop normally and disease phenotypes are subtle 
[102]. The most prominent phenotype in the Nrf2-/- mouse is an increased sensitivity to 
oxidative stress in multiple organ systems [103-106]. Nrf2 overexpression has shown 
therapeutic potential in mouse models of liver toxicity [107], cardiac ischemia, and 
neurodegeneration [108, 109], but this strategy has not been examined using AAV-mediated 
                                                     
7 Adapted in part from NIA/NIH Ruth L. Kirschstein National Research Service Award grant number 5-F30-
AG044100-03 “AAV vectors for retinal delivery in a mouse model of age-related retinopathy”. 
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gene therapy techniques. Therefore, we have explored overexpression of Nrf2 as a potential 
therapeutic vector by which downstream antioxidant genes may be overexpressed in 
appropriate physiological ratios to regain redox homeostasis. 
2.2 AAV-Nrf2 expression in vitro 
Wild-type Nrf2 and the Nrf2-ETGE deletion mutant were cloned into a TR-CBh AAV 
expression plasmid and packaged into an AAV2.5 capsid, a capsid previously engineered in the 
Samulski lab that combines the improved transduction properties of AAV1 with reduced 
antigenic cross-reactivity against antibodies directed at both parental serotypes while keeping 
the receptor binding properties of AAV2 [45]. AAV2.5-Nrf2 overexpression and ARE-driven gene 
expression was confirmed by western blot (Figure 2.2). ARE-driven genes examined included -
glutamylcysteine synthetase (-GCSm) and heme oxygenase-1 (HO-1), the latter which was also 
knocked down by Nrf2 siRNA (Figure 2.2C). AAV vector yields were comparable to reporter 
genes suggesting the Nrf2 transgene is neither toxic nor inhibitory to AAV vector production. 
Wild-type Nrf2 overexpression successfully drives the ARE compared to control plasmid 
transfection as measured by a dual luciferase assay in which Nrf2 activity is measured as a 
function of ARE-driven luciferase activity (Figure 2.3A). Furthermore, an additional vector was 
tested for in vitro activity – a degradation-resistant Nrf2 mutant in which the four amino acids 
comprising the high affinity ETGE Keap1 binding domain are deleted [110]. Notably, the Nrf2-
ETGE mutant exhibited higher levels of ARE activity than wild-type Nrf2 in the presence of 
Keap1, while in the absence of Keap1, Nrf2-ETGE exhibited ARE activation that was significantly 
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greater than wild-type Nrf2 in only two out of the three biological replicates that were 
performed (Figure 2.3, APPENDIX A). 
The ability of AAV-Nrf2 to break down free radicals was further evaluated in an in vitro 
assay of induced oxidative stress (Figure 2.3B). HEK293T cells were transduced with AAV-Nrf2 
or AAV-Luciferase and subjected to H2O2 and arsenic trioxide-induced oxidative stress. AAV-
mediated overexpression of Nrf2 resulted in a reduction in H2O2 and arsenic trioxide-induced 
ROS levels relative to control AAV-Luciferase-treated wells as measured by fluorescence levels 
using an oxidative stress fluorescent indicator dye (CM-H2DCFDA, Invitrogen). 
2.3 Acetaminophen-induced hepatotoxicity as a model of oxidative stress 
In order to evaluate the therapeutic potential of AAV-Nrf2, a mouse model was sought 
for testing in vivo. One of the most straightforward animal disease models caused directly by 
free radicals, and in particular reactive oxygen species (ROS) and reactive nitrogen species 
(RNS), is acetaminophen-induced hepatotoxicity. Following ingestion, acetaminophen (APAP) is 
metabolized in the liver into a reactive intermediate, NAPQI, which in turn causes a cascade of 
ROS and RNS to form, resulting in mitochondrial dysfunction and cell death (Figure 2.4) [111]. 
Nrf2 acts on multiple levels to degrade free radicals by upregulating antioxidant enzymes to 
neutralize reactive intermediates. 
Acetaminophen-induced hepatotoxicity was a particularly attractive model in which to 
evaluate the therapeutic potential of AAV-mediated expression of Nrf2 as therapeutic proof-of-
concept due to the increased susceptibility of Nrf2 knockout mice to acetaminophen-induced 
liver damage [103]. Nrf2-/- mice exhibit decreased survival compared to wild-type mice 
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following APAP administration, a previously published finding [103] I was able to independently 
replicate (Table 2.1). Liver-specific knockdown of Keap1 has also been shown to protect mice 
against acetaminophen-induced hepatotoxicity beyond wild-type levels [107]. Therefore, 
acetaminophen-induced hepatotoxicity was used as a proof-of-concept model in which to test 
the therapeutic potential of AAV-Nrf2 gene replacement in Nrf2-/- mice, as well as 
overexpression in wild-type mice. 
2.4 AAV-Nrf2 expression in vivo 
Based on previously published studies, an AAV8 capsid was used to maximize liver 
transduction [112, 113]. Longitudinal expression studies were performed using a firefly 
luciferase reporter gene packaged into an AAV8 capsid. 1x1010 vector genomes AAV8-Luciferase 
was tail vein injected in Nrf2-/- and wild-type mice and luciferase expression evaluated at 
various time points using in vivo whole-body bioluminescent imaging. Nrf2-/- did not differ 
significantly from wild-type mice in liver transduction levels. Expression levels were further 
compared between CBh and CBA promoters and the CBA promoter was chosen based on the 
outcome of these studies (Figure 2.5). 
2.5 AAV-Nrf2 mediated protection from acetaminophen-induced hepatotoxicity 
AAV8-CBA-Nrf2 was tail vein injected into adult male wild-type and Nrf2-/- mice (1x1012 
vector genomes per animal). Four weeks following AAV injection, mice were challenged with 
lethal doses of APAP – 600 mg/kg for Nrf2-/- mice and 1000 mg/kg for wild-type mice 
(determined by pilot studies based on previously published data [103, 107], data not shown). 
AAV-Nrf2 gene replacement dramatically increased survival following 600 mg/kg APAP 
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administration in Nrf2-/- mice to wild-type levels, and use of the degradation-resistance Nrf2-
ETGE mutant yielded similar results (Table 2.2). Interestingly, AAV-mediated overexpression of 
Nrf2 in wild-type mice did not result in increased survival against 1000 mg/kg APAP at one week 
post-administration, although some level of protection may have been conferred at the three-
day time point (Table 2.3). 
When challenged with sub-lethal doses of APAP, AAV-Nrf2 conferred a slight but 
insignificant decrease in liver enzymes aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) compared to mice that did not receive vector (Figure 2.6). Nrf2-/- mice 
receiving AAV-Nrf2-WT showed a slight, insignificant decrease in liver enzymes following 300 
mg/kg APAP. However, AAV-Nrf2-ETGE pretreatment resulted in increased ALT levels, though 
this difference was also not significant (Figure 2.6A). Interestingly, AAV-Nrf2 conferred 
consistent, though also insignificant, protection against 600 mg/kg APAP administered to wild-
type mice as measured by liver enzymes compared to no virus controls (Figure 2.6B). Consistent 
with the trend of survival data in wild-type mice, AAV-Nrf2-ETGE did not provide protection as 
measured by liver enzymes, and may in fact have led to increased liver enzymes though again, 
this difference was not significant. 
Following harvesting of plasma for liver enzyme measurement, Nrf2-/- mice and wild-
type mice were euthanized and livers collected for sectioning and H&E staining. Exposure to 
APAP resulted in a classic centrilobular necrosis, as evidenced by pale pink necrotic hepatocytes 
surrounding the central vein compared to undamaged darker pink hepatocytes elsewhere 
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(Figure 2.7A, D). Necrosis is not evident in liver sections from mice treated with AAV-Nrf2-WT 
(Figure 2.7B, E). AAV-Nrf2-ETGE confers an intermediate phenotype (Figure 2.7C, F). 
2.6 Discussion 
In this chapter, we explored the development of several novel AAV vectors carrying the 
Nrf2 gene and characterized its expression and activity in vitro and in vivo. AAV-Nrf2 
transduction of cells resulted in measurable protein production and downstream gene 
activation, as evidenced by western blot. Nrf2 constructs also resulted in the activation of the 
ARE promoter, as measured by a dual luciferase assay. As expected, promoter activation was 
found be even greater in a degradation-resistant mutant of Nrf2, Nrf2-ETGE, especially in the 
presence of the cytoplasmic repressor, Keap1, which binds the ETGE motif on the Nrf2 protein. 
Functionally, Nrf2 also muted oxidative stress in vitro, as measured by an ROS assay using a 
fluorescent oxidative stress indicator. 
In vivo, AAV-Nrf2 was evaluated in the context of gene replacement in Nrf2-/- mice, as 
well as overexpression in wild-type mice. An acetaminophen hepatotoxicity model was chosen 
as a proof-of-concept model to evaluate the therapeutic potential of AAV-Nrf2 based gene 
therapy. AAV-Nrf2 gene replacement successfully prevented acetaminophen-induced lethality 
in Nrf2-/- mice, and results using the AAV-Nrf2-ETGE mutant were similar. On the other hand, 
AAV-Nrf2-mediated overexpression in wild-type mice did not confer nearly as dramatic of 
protection from acetaminophen-induced lethality. Nevertheless, the survival results of wild-
type mice from the three day time point suggest that AAV-mediated overexpression of Nrf2 
may have provided a small level of protection against acetaminophen lethality. Contrary to the 
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hypothesis that the degradation-resistant mutant, Nrf2-ETGE, would provide greater Nrf2 
activity and therefore greater protection, wild-type mice given AAV-Nrf2-ETGE were not 
protected from acetaminophen-induced lethality. 
In examining the liver enzyme and histological characterization of acetaminophen 
hepatotoxicity, AAV-Nrf2-treated mice exhibit a trend toward improved liver enzymes and 
decreased necrosis on histology when compared with animals not receiving virus. This trend 
held true in both gene replacement in Nrf2-/- mice and overexpression in wild-type mice, 
though these trends are not statistically significant. Again, results from AAV-Nrf2-ETGE treated 
mice did not show as large of a trend toward rescue in either case as the AAV-Nrf2-WT treated 
mice did. 
One possible explanation for the lack of convincing survival data from Nrf2 
overexpression is that the dose of acetaminophen chosen to challenge wild-type mice may 
have overwhelmed the system’s ability to recover. It is well known that the lethal dosing curve 
for acetaminophen is very steep, as evidenced by its high ED50/LD50 ratio, a ratio comparing 
the effective dose to the lethal dose of half the population [114]. More extensive pilot studies 
parsing out the exact dosing curve in wild-type mice may identify a lethal dose less than 
1000mg/kg in which AAV-mediated overexpression of Nrf2 could be beneficial. Interestingly, 
liver enzyme results from wild-type mice showed greater differences between those 
overexpressing Nrf2 and those not receiving virus than the Nrf2-/- cohorts. Because wild-type 
and Nrf2-/- mice received different doses of APAP, they cannot be directly compared except in 
Table 2.1. However, this underscores the effect of testing prevention of hepatotoxicity at APAP 
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doses that may be too high to rescue or too low to see an effect. Previous studies using genetic 
hepatic-specific knockdown of the cytoplasmic repressor, Keap1, effectively result in increased 
Nrf2 availability and result in increased tolerance of mice to acetaminophen hepatotoxicity 
[107]. This suggests that the biological concept of Nrf2 overexpression should confer 
protection. 
As a final word, several difficulties exist in comparing studies and extrapolating results 
from study to study. Firstly, fasting protocols can greatly affect the magnitude of toxicity that 
occurs. Previous studies have shown that fed mice are less susceptible to toxic effects of 
acetaminophen than fasted mice [115]. Secondly, the vehicle and delivery route can also 
greatly impact the degree of toxicity that is experienced [116]. Thirdly, gender differences exist 
in susceptibility to acetaminophen toxicity [117]. Therefore, thorough pilot studies are essential 
to defining testing parameters of this, and likely any, study. 
2.7 Future directions 
AAV-Nrf2 conferred a straightforward protection from acetaminophen-induced 
hepatotoxicity in which AAV-Nrf2-injected animals saw a survival benefit, and exhibited livers 
that were less damaged than those of uninjected animals, all on a timecourse of days. The 
straightforward survival benefit seen by AAV-Nrf2 injected animals suggests that Nrf2 is acting 
in its canonical role as a transcription factor for antioxidant genes to mediate liver protection 
from acetaminophen toxicity. In order to confirm this, further studies should be done to 
confirm downstream antioxidant gene expression as well as to examine levels of reactive 
oxygen species in the liver. Downstream antioxidant gene expression should be carried out by 
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western blotting liver lysates from animals that are uninjected, compared with animals that 
were injected with either AAV-Nrf2-WT or AAV-Nrf2-ETGE. Further comparisons should be done 
with injected and uninjected mice that were administered acetaminophen compared to those 
given vehicle. Because Nrf2 avoids degradation to some extent under conditions of oxidative 
stress, it would be interesting to see if Nrf2 could be detected by western blot following 
acetaminophen stress. Preliminary experiments suggest that even under conditions of oxidative 
stress, in vivo Nrf2 is not detectable via western blot using commercially available antibodies 
(data not shown); however careful troubleshooting is necessary to confirm this assertion with 
certainty. Levels of downstream antioxidant heme oxygenase 1 are detectable on western blot 
of retinal lysates from eyes injected with AAV-Nrf2 (Figure 3.2), suggesting that the same 
should be true of livers from mice that have been tail vein injected with AAV-Nrf2. Western 
blotting over other downstream genes would further confirm activation of the Nrf2-ARE 
pathway. 
In order to further determine AAV-Nrf2 function in the observed hepatoprotection, 
levels of reactive oxygen species and oxidative damage could be measured in injected and 
uninjected mice following acetaminophen administration. Levels of reactive oxygen species are 
commonly measured using administration of dihydroethidine, a compound that reacts with 
oxygen free radicals to form ethidium bromide, which fluoresces red [118]. Oxidative damage 
could be further measured by immunostaining for markers of oxidative damage, including 
nitrotyrosine, acrolein, and 8-hydroxydeoxyguanosine [119]. Protein carbonyl content can also 
be measured by ELISA [120]. The upregulation of antioxidant genes, together with evidence of 
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AAV-Nrf2 mediated protection from measurable oxidative stress levels and oxidative damage 
would strongly support an antioxidant mechanism for AAV-Nrf2-mediated protection from 
acetaminophen-induced hepatotoxicity. 
2.8 Experimental procedures 
2.8.1 Plasmids 
Wild-type and ETGE deletion Nrf2 plasmids were kind gifts from Yue Xiong [110]. Keap1 
and luciferase plasmids used in the dual luciferase assay were kind gifts from M. B. Major [121]. 
AAV production and packaging plasmids, including TR-CBh and TR-CBA AAV expression 
plasmids, pXX680, pXR2.5, and pXR8 have previously been used extensively in the Samulski lab 
[35, 45, 112]. 
2.8.2 Cell culture, transfections, transduction, and virus production 
All cell culture assays were conducted using HEK293T cells maintained in Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented with 10% Fetal bovine serum, 100 U/ml 
penicillin, and 100 g/ml streptomycin. Transfections for western blotting and virus production 
were performed using Polyethylenimine ‘Max’ (linear, MW 25 000) (Polysciences, Inc.), except 
for siRNA experiments which were performed using lipofectamine RNAiMax (Life Technologies). 
Transfections for the dual luciferase assay were carried out using Lipofectamine 2000 (Life 
Technologies). Transductions were performed at the specified multiplicity of infection (MOI) 
Virus was produced, purified, and characterized as previously described [35]. Briefly, 
AAV was produced in HEK293T cells using the triple transfection method and purified on 
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continuous cesium gradient and dialyzed three times against phosphate buffered saline (PBS). 
Vector yield was assayed using quantitative PCR for viral genomes. 
2.8.3 SDS-PAGE and western blotting 
Cells were lysed with RIPA buffer (1% NP40, 0.1% SDS, 0.25% sodium deoxycholate, 
150mM NaCl, 10% glycerol, 25mM Tris pH 7-8, 2mM EDTA) with protease inhibitor (Halt 
protease inhibitor cocktail, Life Technologies) on ice with a cell scraper. Lysates were subjected 
to one freeze-thaw cycle, then spun down at 13,000 rpm for 5 minutes at 4⁰C. Protein from 
supernatants was quantified using a Bio-Rad protein assay and samples were prepared with 
loading dye (Laemmli Buffer, Bio-Rad) and DTT (2mM) and boiled for 5 minutes prior to loading 
on 10% Tris-glycine Mini Protean-TGX protein gels for SDS-PAGE (Bio-Rad). 
For western blotting, a dry transfer system was used (iBlot, Invitrogen). Nitrocellulose 
membranes were blocked with 5% milk, incubated with primary antibody overnight at 4⁰C, and 
secondary antibody at room temperature for 30 minutes. Antibodies used were as follows: 
rabbit anti-Nrf2-H300 (Santa Cruz), rabbit anti-HO-1 (Abcam), rabbit anti- GCSm (Santa Cruz), 
mouse anti--actin (Abcam), rabbit anti-GAPDH (Santa Cruz). 
2.8.4 Dual Luciferase assay 
HEK 293T cells were co-transfected with ARE-Firefly Luciferase, CMV-Renilla Luciferase, 
and Keap1 expression plasmids, along with AAV TR plasmids CBA-AAT, CBh-Nrf2-WT, or CBh-
Nrf2-ETGE. Cell lysate was prepared according to manufacturer’s instructions and aliquoted 
into 96-well opaque white cell culture plates for analysis (Promega Dual Luciferase Reporter 
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Assay System). Luciferase activity was read in a luminescence plate reader and Nrf2 activity 
quantified at 24 hours following transfection as a ratio of Firefly to Renilla luciferase. 
2.8.5 Fluorescent ROS assay 
HEK 293T cells were plated in 96-well clear bottomed black cell culture plates and 
transduced with 50,000 MOI AAV-Nrf2-WT or control AAV carrying a luciferase reporter gene. 
40 hours following infection, cells were stressed with 1mM H2O2 (Sigma-Aldrich) and 50M 
arsenic trioxide. As2O3 (Sigma-Aldrich) was prepared as a 1 mM stock solution in 200 mM NaOH 
and compared to a vehicle control of the same pH. Levels of resulting ROS were measured in a 
fluorescence plate reader using an intracellular oxidative stress fluorescent indicator dye (5mM 
CM-H2DCFDA, Invitrogen). 
2.8.6 Mice and in vivo imaging 
C57Bl/6J mice were purchased from The Jackson Laboratory. Nrf2-/- mice were a kind 
gift from Steven Kleeberger and backcrossed nine times to C57Bl/6J by Jenny Ting. All 
experiments were performed using adult mice (2-6 months old). All mice were maintained and 
bred in UNC animal facilities and all animal experiments were conducted in accordance with the 
policies of the Institutional Animal Care and Use Committee at the University of North Carolina 
at Chapel Hill. Inhalable isofluorane was used for anesthesia in all cases where anesthesia was 
required. 
Live whole animal bioluminescent imaging was performed using an IVIS Kinetic optical 
imaging system in the Biomedical Research Imaging Center at The University of North Carolina 
at Chapel Hill as previously described [122]. Briefly, 150 mg/kg D-luciferin (Caliper LifeSciences) 
36 
 
was administered by i.p. injection, and luminescence was imaged after five minutes. The Igor 
Pro 3.0 software was used to quantitate luminescence signals. 
2.8.7 Acetaminophen-induced hepatotoxicity 
Acetaminophen administration was carried out as previously described [103]. Briefly, 
mice were fasted for 16 hours overnight prior to acetaminophen administration. 
Acetaminophen (Sigma-Aldrich) was dissolved in 50% propylene glycol (Sigma-Aldrich) in sterile 
water and administered to mice via oral gavage at either 300, 600, or 1000 mg/kg as indicated. 
Blood was collected from mice at 8 hours following APAP administration via retro-orbital bleed 
using heparinized capillary tubes. 
Mice were euthanized and livers were harvested immediately at 24 hours following 
APAP administration and immersed in 10% normal buffered formalin. Fixed tissues were 
embedded in paraffin and sectioned into 10m sections. Sections were stained with 
hematoxylin and eosin according to conventional staining protocols and imaged using 
conventional bright field microscopy. All histological sectioning and staining was carried out by 
the UNC Cystic Fibrosis Center Histology Core Facility. 
2.8.8 Statistical analysis 
Statistical significance for the dual luciferase assay was assessed using a linear mixed 
effects regression model, performed at The North Carolina Translational and Clinical Sciences 
Institute (APPENDIX A). Statistical significance for the fluorescent ROS assay was assessed using 
a paired samples t-test to compare ROS levels in AAV-Nrf2 infected cells vs. AAV-Luciferase cells 
from the same experiment. 
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2.9 Figures and Tables 
 
 
Figure 2.1. ARE-Nrf2 signaling – a simplified model. 
In redox homeostasis, the Keap1 homodimer targets Nrf2 for ubiquitination and proteasome 
degradation. Oxidative stress signals trigger a conformational change in Keap1-Nrf2 binding 
which prevents proteasomal targeting. Presumably this allows newly synthesized Nrf2 
translocation to the nucleus, Nrf2-Maf heterodimer binding to the ARE, and downstream gene 
activation. Dashed lines indicate mechanisms under active investigation. The ARE is contained 
in the promoter region of numerous antioxidant and Phase II detoxifying enzymes, including 
glutathione recycling enzymes and hemoxygenase-1 to name a few [106, 123, 124]. 
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Figure 2.2. AAV-Nrf2 transduction drives Nrf2 and downstream gene expression in vitro. 
(A) Western blot verifying Nrf2 expression following transduction of 293T cells with AAV2.5-
CBh-Nrf2. Rb α-Nrf2 antibody detects band of ~110kb, arrowhead = nonspecific band. Lane 1: 
no virus; Lanes 2, 3: AAV-Nrf2; Lanes 4,5: AAV-AAT control. Lanes 2, 4: 10,000 MOI; Lanes 3, 5: 
50,000 MOI. (B) Western blot and corresponding densitometric quantitation of total γ-
glutamylcysteine synthase(γ-GCSm) downstream gene activation following pAAV-Nrf2 
transfection compared to luciferase control. (C) Western blot and corresponding densitometric 
quantitation of pAAV-Nrf2-induced heme oxygenase-1 (HO-1) gene activation and Nrf2-siRNA 
repression compared to pAAV-AAT transfection control. Lanes 1, 4: none; Lanes 2, 4: pAAV-
CBA-AAT; Lanes 3, 6: pAAV-CBh-Nrf2. 
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Figure 2.3. Nrf2 drives the ARE and decreases ROS in vitro. 
(A) Nrf2 activity was quantified as a ratio of Firefly to Renilla luciferase following transfection of 
HEK293T cells with ARE-Firefly Luciferase, CMV-Renilla Luciferase, and Keap1 expression 
plasmids, along with AAV packaging plasmids CBA-AAT, CBh-Nrf2-WT, or CBh-Nrf2-ETGE. Assay 
was performed in triplicate and data is reported for three separate biological replicates. 
p<0.0001 for all comparisons except Nrf2-WT vs. Nrf2-ETGE in the absence of Keap1 (APPENDIX 
A). (B) Fluorescent ROS assay was used to measure H2O2 and arsenic-induced oxidative stress 
levels in HEK293T cells transduced with 50,000 MOI AAV-Luciferase or AAV-Nrf2. Plotted values 
represent the ratio of fluorescence measured in cells stressed with H2O2 and arsenic compared 
to reference cells treated with vehicle (n=7, p<0.05, *, paired t-test). 
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Figure 2.4. Mechanisms of acetaminophen liver toxicity. 
Acetaminophen is partially metabolized in the liver via glucuronyltransferases and 
sulfotransferases into a nonreactive conjugate that can be directly eliminated. However, the 
capacity of these enzymes must be partially supplemented by cytochrome P450-mediated 
metabolism, producing the reactive intermediate NAPQI. NAPQI causes cell necrosis through 
mitochondrial dysfunction and reactive nitrogen and reactive oxygen species. Several Nrf2-
mediated mechanisms act to relieve the system of reactive intermediates and restore 
homeostasis (green). NAPQI can be converted back to acetaminophen by the Nrf2-mediated 
enzyme NQO1 and shunted back toward glucuronyltransferase/sulfotransferase pathways. 
Alternatively, NAPQI and ROS/RNS can be broken down by glutathione peroxidase and 
glutathione S-transferase (both controlled by Nrf2) into products that are able to be eliminated. 
Nrf2 provides additional relief to the system by driving transcription of enzymes involved in 
glutathione recycling and de novo synthesis. Reactive species and toxic effects are indicated in 
red, and first-order acetaminophen metabolism enzymes are indicated in blue. 
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Figure 2.5. AAV-Luciferase drives transduction in vivo. 
C57BL/6J mice were tail vein injected with 1x1010 vector genomes vg/mouse AAV8-luciferase. 
Transduction was assessed by live imaging at 5, 8, 11, and 14* days post-injection. (A) Live 
images are shown for days 5 and 11 post-injection. (B) Luciferase expression is quantified in 
counts per minute (CPM) per region of interest (ROI). *Signal saturated at 14 days. 
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Table 2.1. Survival of Nrf2 knockout mice and wild-type mice exposed to acetaminophen 
 
 Acetaminophen Dose 
300 mg/kg 600 mg/kg 
Time (h) Nrf2-/- WT Nrf2-/- WT 
24 5/5 3/3 4/7 13/14 
48 5/5 3/3 1/7 12/14 
 
 
 
 
Table 2.2. Survival of Nrf2 knockout mice mice treated with AAV-Nrf2 prior to acetaminophen 
administration 
 
 
 
 
Table 2.3. Survival of wild-type mice mice treated with AAV-Nrf2 prior to acetaminophen 
administration 
 
WT mice No virus AAV8-CBA-Nrf2-WT AAV8-CBA-Nrf2-ETGE 
3-day survival 1/8 4/5 1/7 
1 week survival 1/8 1/5 1/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nrf2-/- mice No virus AAV8-CBA-Nrf2-WT AAV8-CBA-Nrf2-ETGE 
3-day survival 1/11 7/7 5/6 
1 week survival 1/11 7/7 5/6 
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Figure 2.6. Plasma AST and ALT activity following acetaminophen administration. 
Adult Nrf2 knockout (A) and wild-type (B) mice were tail vein injected with 1x1012 vector 
genomes AAV8-CBA-Nrf2-WT or AAV8-CBA-Nrf2-ETGE. One month following AAV injection, 
Nrf2-/- and wild-type mice were challenged with 300 mg/kg and 600 mg/kg APAP, respectively. 
Plasma was collected at 8 hours following acetaminophen administration for liver enzyme 
analysis. Error bars represent standard deviation for n=2-4 mice per group. 
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Figure 2.7. Liver morphology following APAP-induced hepatotoxicity. 
Adult Nrf2 knockout and wild-type mice were tail vein injected with 1x1012 vector genomes 
AAV8-CBA-Nrf2-WT (B, E) or AAV8-CBA-Nrf2-ETGE (C, F). One month following AAV injection, 
Nrf2-/- and WT mice were challenged with 300mg/kg and 600mg/kg acetaminophen, 
respectively. Livers were harvested at 24 hours following acetaminophen administration for 
sectioning and H&E staining. 
 
45 
 
 
CHAPTER 3: Intravitreal AAV-mediated expression of Nrf2 promotes recovery after light-
induced retinal damage in mice8 
 
3.1 Light-induced retinopathy as a model for retinal degeneration 
Exposure to high levels of light has become a standard model for studying retinal 
degeneration, in particular age-related macular degeneration (AMD) [125]. AMD is the leading 
cause of blindness in the United States [126], with 1.75 million citizens affected in the year 
2000 [127], and a projected increase to 2.95 million by the year 2020 [127]. While AMD is a 
multifactorial disease, lifetime light exposure has long been implicated as a risk factor in AMD 
pathogenesis [128, 129]. Notably, light-induced retinal degeneration recapitulates many 
features of AMD more closely than many other immunologic or genetic animal models in 
current use [130]. Over the years, many studies have utilized exposure to bright light to study 
retinal pathogenesis, and have discovered nuances in its underlying mechanisms across animal 
strain and species [131] and even different light exposure protocols [125, 132]. This suggests 
that retinal pathogenesis mechanisms in general may vary from species to species, and even 
within the same species, there may be parallel mechanisms that complicate our understanding 
of disease progression and discovery of therapeutic targets. Nevertheless, this accelerated 
                                                     
8 Adapted in part from NIA/NIH Ruth L. Kirschstein National Research Service Award grant number 5-F30-
AG044100-03 “AAV vectors for retinal delivery in a mouse model of age-related retinopathy”. 
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retinal degeneration system has allowed us to elucidate many key points of pathogenesis, 
which are broadly summarized here. 
 Phototransduction is initiated by the absorption of light by the retinal chromophore 
nestled in the rhodopsin protein (Figure 3.1). The change from 11-cis to all-trans retinal in turn 
results in rhodopsin activation. Activated rhodopsin must be quenched and recycled back to its 
deactivated form by arrestin and rhodopsin kinase. Deficiencies of both arrestin and rhodopsin 
kinase have been implicated in increased susceptibility to light damage, suggesting that 
prolonged rhodopsin activation and subsequent phototransduction may mediate light-induced 
retinopathy [133, 134]. Excessive phototransduction has been further investigated in transducin 
knockout mice, which exhibited increased retinal damage in response to long-term exposure to 
moderate intensity light, but not to that caused by acute exposure to high intensity light [132]. 
This suggests that phototransduction itself is necessary for some, but not all, pathways of light-
induced degeneration. Rhodopsin knockout mice are protected from retinal light damage, as 
are RPE65 knockout mice [135]. Taken together, these results suggest that retinal damage may 
result directly from the magnitude of light absorbed, as mice lacking rhodopsin, as well as mice 
that cannot regenerate the chromophore, absorb less light. 
Reactive oxygen and reactive nitrogen species (ROS, RNS) initiate cell death and also 
play a large role in the pathogenesis of light-induced degeneration (Figure 3.1). Metabolites of 
all-trans retinal absorb light to form free radicals that generate ROS and RNS in the RPE [136]. 
Increased light cycling also increases RPE phagocytosis of outer segments, generating ROS and 
RNS. Lipid membranes, in particular the membranes of the outer segment disks, absorb light 
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and undergo lipid peroxidation, which react with oxygen and nitrogen products to form ROS 
and RNS. Cellular damage recruits microglia, which also produce ROS and RNS. Nitric oxide in 
particular activates cGMP synthesis, disrupting normal homeostatic cGMP cycling, resulting in 
massive opening of cGMP-gated channels [137]. Influx of calcium in particular, together with 
the disruption in membrane potential, causes mitochondrial dysfunction, further ROS and RNS 
generation, and cell death. 
3.2 ARE-Nrf2 signaling and retinal disease 
Due to its high oxygen supply and exposure to high levels of photooxidation, the retina 
is particularly vulnerable to oxidative stress [138]. The reactive processes and large metabolic 
load stemming from photoabsorption and phototransduction as outlined above underscore the 
retina’s vulnerability to oxidative damage. As described in CHAPTER 2, Nrf2 responds to 
elevated levels of oxidative stress by upregulating transcription of antioxidant genes. Perhaps 
unsurprisingly, between 8-12 months of age, Nrf2-deficient mice develop clinical pathological 
features similar to AMD [139]. Consistent with the systemic findings explored in CHAPTER 2, in 
which Nrf2-/- mice exhibited increase susceptibility to oxidative stress in various organisms 
including the liver, young Nrf2-deficient mice exhibit increased susceptibility to hyperoxia in a 
well-established model of induced retinopathy of prematurity [140]. Nrf2 overexpression has 
been demonstrated to successfully dampen the damage caused by various oxidative insults and 
has successfully rescued mouse models of neurodegeneration, [108, 109], but has only recently 
been applied to the eye [141]. 
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Control of oxidative stress shows promise as a therapeutic strategy for retinal 
degeneration. Antioxidant vitamins and supplements are therapeutic for AMD as seen in the 
Age-Related Eye Disease Study, a treatment regimen now considered standard of care [142]. 
While AMD is a multifactorial disease, glutaredoxin 2 is one susceptibility gene linked to both 
AMD and redox homeostasis [143]. The AMD susceptibility gene glutaredoxin is part of the 
thioredoxin superfamily that is regulated by the Antioxidant Response Element (ARE) [144]. ARE 
induction protects against in vitro oxidative stressors [145] and photooxidative damage [146]. 
In the rd10 mouse, a model of retinal degeneration in which oxidative stress is also thought to 
play a role in pathogenesis, overexpression of specific and multiple combinations of antioxidant 
enzymes were required to prevent degeneration [147, 148]. This evidence suggests that precise 
and coordinated overexpression of antioxidant enzymes must be induced in concert to exert 
therapeutic benefit.   
3.3 Gene therapy approaches to eye disease 
 One of the most promising new therapeutic strategies to treat eye disease is gene 
therapy using AAV. Valued for its lack of pathogenicity, low immunogenicity, and ability to 
achieve persistent transgene expression, AAV has been used as a successful therapeutic 
delivery vehicle in over 70 clinical trials to date, including Leber’s Congenital Amaurosis (LCA), a 
form of inherited retinal degeneration [149-151]. Most therapeutic applications have utilized 
AAV serotype 2 as a delivery vehicle, but its limited transduction efficiency has prompted 
exploration of additional capsid serotypes for transgene delivery. To date, 12 serotypes (AAV1-
12) and more than 100 variants have been isolated from human and non-human primate tissue 
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samples [152]. Highly variable surface-exposed loops on the viral capsid confer ability to utilize 
different cell entry receptors, resulting in diverse patterns of tissue tropism and transduction 
efficiency.  
 A major hurdle to retinal gene therapy is the Inner Limiting Membrane (ILM), a barrier 
between the vitreous chamber and retina [153] that prevents first generation AAV vectors 
delivered intravitreally to transduce the retina. To overcome this limitation, AAV vectors must 
be injected subretinally to sufficiently transduce the retina, a procedure that is more invasive 
than the intravitreal injection, an outpatient procedure. Notably, subretinal injections form 
retinal detachments, leading to a damaging microenvironment for cellular remodeling that can 
result in vision loss [154]. Furthermore, subretinal injections provide transduction localized to 
the point of injection, which is not ideal for applications that require global retinal delivery. 
Intravitreal injections, if optimized for efficacy, can offer a much safer, less invasive alternative 
to the subretinal delivery route, with the added possibility of widespread transduction of many 
retinal cell types. 
 To date, gene therapy approaches to eye disease have focused on monogenetic diseases 
such as LCA, utilizing a gene replacement strategy for a single defective gene. Given the genetic 
heterogeneity and multifactorial etiology of many retinal diseases, a more universally 
applicable therapeutic strategy is desirable. One such strategy stems from evidence implicating 
oxidative stress in the pathogenesis of retinal degeneration.  
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3.4 Results 
AAV2.5, which exhibits slightly reduced heparin binding compared to AAV2, was found 
to be superior to AAV2 as a vector for intravitreal retinal delivery in the rodent model (Figure 
3.2). We have since tested AAV2.5 in both pigs and primates, and have found AAV2.5 to be a 
superior vector to AAV2 in all three animal models (unpublished data, personal communication 
with Dr. Jean Bennett, University of Pennsylvania). 
Nrf2 was cloned into an AAV TR-CBh expression plasmid, packaged into an AAV2.5 
capsid, and tested in vitro as previously described (Section 2.2). AAV-Nrf2 was injected 
intravitreally and expression was assessed by western blot eight months following injection 
(Figure 3.2C). While Nrf2 protein was not detectable in retina lysate, the canonical Nrf2 readout 
ARE-controlled heme oxygenase-1 (HO-1) was strongly upregulated compared to control lysates 
from uninjected eyes of both Nrf2-/- and wild-type mice. 
3.4.1 AAV-Nrf2-mediated protection from severe light damage 
To test the therapeutic potential of AAV-Nrf2 in retinal disease, a light-induced 
retinopathy model was employed. Adult Balb/C mice were intravitreally injected with AAV-Nrf2 
in one eye and the fellow eye was left uninjected as an internal control. Six weeks following 
injection, mice were exposed to 4000 lux of bright white light for three hours, which resulted in 
a severe retinal degeneration. Retinal morphology was monitored using in vivo optical 
coherence tomography retinal imaging. Total retinal thickness was measured in four cardinal 
directions relative to the optic nerve and plotted on spider plots to compare eyes injected with 
AAV-Nrf2 to uninjected eyes at various time points following light damage, as well as to mice 
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naïve to both injection and light damage (Figure 3.3). At three hours following exposure to light 
damage, total retinal thickness was highly variable, likely owing to acute cell stress response 
and inflammation in the hours following acute stressors (Figure 3.3A, B). At three months 
following exposure to light damage however, clear differences are present in total retinal 
thickness between injected and uninjected eyes (Figure 3.3 C, D). Uninjected eyes exposed to 
bright white light exhibit severely degenerated retinas, with total retinal thickness far less than 
that of naïve mice. AAV-Nrf2 injected eyes appear to have some preservation of retinal 
thickness, exhibiting an intermediate phenotype between uninjected and totally naïve eyes. 
H&E staining revealed wildly variable retinal structure in uninjected eyes exposed severe 
light damage compared to both AAV-Nrf2-injected eyes exposed to light damage as well as to 
eyes naïve to injection and light damage (Figure 3.4). Severe photoreceptor loss is exhibited by 
areas of massive ONL thinning, as well as shortening of photoreceptor inner and outer 
segments (Figure 3.4E). Some areas remain where the ONL is of similar thickness to injected 
eyes exposed light damage, but overall the uniform laminar structure of the retinal layers is 
severely disrupted (Figure 3.4B). Consistent with the measurements of total retinal thickness, 
qualitatively, eyes injected with AAV-Nrf2 prior to exposure to severe light damage maintain an 
intermediate phenotype between uninjected eyes exposed to light damage and eyes naïve to 
injection and light damage. While some photoreceptor degeneration has occurred, as 
evidenced by thinning of the ONL and shortening of inner and outer segments, AAV-Nrf2-
injected eyes maintain uniform laminar retinal layers similar to naïve retinas (Figure 3.4C, F). 
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In order to further characterize the features of retinal light damage and translate these 
qualitative findings into quantifiable data for comparison, OCT images were blinded and scored 
for pathological features as described in Section 3.7.6. Retinal pathology scores were then 
compared between injected and uninjected eyes exposed to severe light damage. As expected, 
uninjected eyes exhibited more pathological features than injected eyes (Figure 3.5B). 
In addition to histological pathology, retinal function was also measured using 
electroretinogram (ERG) at various time points following exposure to severe light damage. ERGs 
reveal diminished but highly variable signals at one week following exposure to 4000 lux bright 
white light for 2 hours (Figure 3.6A, C). At three months following light damage, a and b wave 
amplitudes are severely diminished in uninjected eyes, whereas modest function is maintained 
in AAV-Nrf2 injected eyes (Figure 3.6B, D). All eyes exposed to severe light damage however 
exhibit a and b wave amplitudes that are significantly diminished compared to eyes naïve to 
injection and light damage. 
3.4.2 AAV-Nrf2 mediated rescue from moderate light damage 
In order to further optimize AAV-Nrf2 for maximal therapeutic potential, we employed a 
Nrf2 mutant in which the high affinity Keap1 binding domain has been deleted. The Nrf2-ETGE 
mutant has been shown in previous studies to exhibit a decreased Keap1 binding affinity [110], 
presumably increasing the availability of newly synthesized Nrf2 to avoid ubiquitination and 
translocate to the nucleus and activate transcription. We have shown that the Nrf2-ETGE 
mutant does indeed drive the ARE to a greater degree than wild-type Nrf2 in the presence of 
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Keap1 (Figure 2.3). Accordingly, Nrf2-ETGE was cloned into a TR-CBh AAV expression plasmid 
and packaged into an AAV2.5 capsid as described in CHAPTER 2. 
To test the therapeutic potential of the Nrf2 ETGE mutant, AAV2.5-CBh-Nrf2-ETGE was 
injected intravitreally injected in adult Balb/C mice. Four months following injection, mice were 
exposed to 4000 lux of bright white light for two hours, which resulted in a moderate retinal 
degeneration. Retinal morphology was again monitored using OCT retinal imaging and total 
retinal thickness was measured and plotted on spider plots to compare eyes injected with AAV-
Nrf2-ETGE with uninjected eyes. Retinal thickness measurements revealed that total retinal 
thickness displayed no statistically significant differences between treated and untreated eyes 
(Figure 3.3E-H). When comparing retinal thickness from mice naïve to injection and light 
damage, both uninjected mice and mice injected with AAV-Nrf2-ETGE exhibited a slight but 
significant decrease in retinal thickness in the nasal-temporal axis (Figure 3.3E) but not the 
inferior-superior axis (Figure 3.3F). By one month following light damage, AAV-Nrf2-ETGE 
injected mice had recovered retinal thickness comparable to that of naïve mice, especially in 
the nasal-temporal axis (Figure 3.3G) and to a lesser extent in the inferior-superior axis (Figure 
3.3H). Meanwhile, retinal thickness of uninjected animals remained thinner than that of naïve 
animals on both axes (Figure 3.3G, H). 
Retinal pathology was further characterized by pathology scoring of blinded OCT scans 
as described in Section 3.7.6. Retinal pathology scores were then compared between injected 
and uninjected eyes exposed to moderate light damage. Surprisingly, AAV-Nrf2-ETGE injected 
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retinas scored higher on the retinal pathology score scale than uninjected retinas exposed to 
moderate light damage (Figure 3.5C). 
Retinal function was also evaluated by ERG and was found to be severely diminished in 
both injected and uninjected eyes at one week following exposure to moderate light damage 
(Figure 3.7A, C). However, by one month following light damage, eyes injected with AAV-Nrf2 
had recovered function equal to, if not surpassing, age-matched animals naïve to AAV and light 
damage (Figure 3.7B, D). 
3.5 Discussion 
In cases where therapeutic effect is suboptimal, several different strategies can be 
employed to increase transgene expression in the hopes of increasing therapeutic efficacy. 
Increasing the amount of virus delivered has its limitations as you increase risk of triggering 
immune response to viral particles. Evaluating promoter strength can be useful, as outlined in 
Figure 2.5. Optimizing transgene codons has become a common strategy as well [155]. 
However, in some cases, mutations in the actual amino acid sequence of the protein can result 
in increased activity or availability of the protein. This strategy has previously been utilized 
successfully in another gene therapy application that is currently undergoing clinical trials [156]. 
In this study, we employed a Nrf2 mutant in which its Keap1 high affinity ETGE binding motif 
has been deleted, allowing for increased Nrf2 translocation to the nucleus and transcriptional 
activation. 
We therefore applied the AAV-Nrf2-ETGE mutant to the light induced retinopathy model 
and found that AAV-Nrf2-ETGE is capable of rescuing retinal function in mice to levels beyond 
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that of age-matched mice naïve to injection and light damage. Our ERG recordings suggest that 
we are able to rescue beyond age-matched naïve levels due to the slow, mild retinal 
degeneration that is known to affect albino Balb/C mice in normal 12:12h light-dark cycle even 
in the low levels of room light present in most routine animal housing facilities [157, 158]. As 
depicted in Figure 3.8, ERG a and b wave amplitudes are slightly diminished between two and 
four months of age in mice naïve to light damage and injection. However, even AAV-Nrf2-WT 
injection at two months of age seems to prevent this slight decrease in retinal function seen 
with age. 
An interesting feature of the AAV-Nrf2-mediated rescue of moderate light-induced 
retinal damage is that function of both injected and uninjected eyes are equally impaired at the 
one week timepoint. By one month, the AAV-Nrf2 injected eyes recover full function whereas 
the uninjected eyes exposed to moderate light damage do not recover. This suggests that AAV-
Nrf2 is acting to promote retinal recovery and perhaps regeneration following injury, rather 
than acting to protect retinal damage from occurring. The retinal pathology scoring from 
animals in this cohort further supports the possibility of increased tissue repair and remodeling, 
rather than a preservation of morphology. As seen in Figure 3.5C, AAV-Nrf2-injected eyes were 
scored to exhibit greater “retinal pathology” than uninjected eyes exposed to moderate light 
damage. However, the improvement in retinal function in AAV-Nrf2-injected eyes but not 
uninjected eyes exposed to light damage contradicts this result. One possible explanation is 
that the features that were interpreted as “pathological” in the AAV-Nrf2-injected eyes were 
actually areas where regeneration and/or repair had occurred. This is particularly worth noting, 
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as most investigation into Nrf2 function examines its role in combating oxidative stress, a 
function that would occur on the timescale of hours to days, not weeks. 
Indeed, the role of Nrf2 in tissue repair and regeneration is only beginning to be 
explored [159, 160]. It is only natural that these alternative roles for Nrf2 have largely been 
explored in the liver given its relatively simple structure composed of mainly one cell type, as 
well as its known regenerative potential. Nevertheless the eye is a useful system in which to 
study these functions as well, and may indeed serve to enhance our understanding of the role 
of Nrf2 in tissue repair and regeneration even further. The retina’s unique characteristics of 
continual phagocytosis of photoreceptor outer segments by the RPE, as well as regenerative 
potential of Muller glia cells, make it an interesting and potentially useful system in which to 
conduct further investigation of Nrf2-dependent stress response, tissue repair, and 
regeneration. 
An alternative, less enticing explanation for the timescale of damage followed by rescue 
at longer time points could simply be that retinal cells are functionally damaged or in a state of 
“shock” following light damage. It is possible that these cells never die and are not actually 
replaced by regeneration of cells, but simply nonfunctional at short time points. In this 
explanation, AAV-Nrf2 would mediate protection that manifests as a functional recovery at long 
time points, with cell death eventually occurring in corresponding uninjected eyes. This 
explanation does not reconcile the difference in retinal pathology score seen in retinas that 
have been exposed to moderate light damage, the cause of which remains elusive. 
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During the preparation of this manuscript, another manuscript successfully 
demonstrated the use of AAV-Nrf2 in several eye disease models, including rd1, rd10, and Rho-
/- genetic mouse models as well as optic nerve crush [141]. It is worth noting that while AAV-
Nrf2 appeared to promote cone survival and function in the retinitis pigmentosa mouse 
models, as well as ganglion cell survival following optic nerve crush, the underlying mechanisms 
at play may differ slightly from what we observe in the present study. The retinitis pigmentosa 
models exhibit varying degrees of retinal degeneration starting at birth, so AAV injection was 
conducted at P0, and AAV-mediated expression of Nrf2 appeared to slow degeneration both 
histologically and functionally. However, one would hypothesize that the mechanisms 
underlying the optic nerve crush model may be more directly comparable to our present study, 
not due to the cell types involved, but due to the context of response to acute injury. While 
retinal function diminished immediately following moderate light damage, function in AAV-Nrf2 
injected eyes recovered by one month. At one month following optic nerve crush, Xiong et al. 
observed a continued decline in ganglion cell survival. Because retinal function was not 
evaluated in animals subjected to optic nerve crush, results are not necessarily comparable; 
however the differences in observation of pathology over the same time course are interesting 
to note. 
Oxidative stress is observed in many chronic diseases, diseases of the eye in particular. 
Our results join those of Xiong et al. in support of the therapeutic potential of AAV-Nrf2 for the 
treatment of a wide variety of retinal diseases. Our findings broaden the scope even further to 
open up the possibility of AAV-Nrf2 as a treatment for AMD, the leading cause of blindness in 
58 
 
the developed world. In addition to providing protection from oxidative damage, our results 
suggest a role for Nrf2 in tissue regeneration and repair. Further studies are necessary to 
elucidate the mechanisms that are involved in executing the therapeutic benefit derived from 
Nrf2 overexpression, which may vary across different diseases, organ systems, and species. 
3.6 Future directions 
The work completed in this dissertation suggests a therapeutic role for Nrf2 in oxidative 
stress disease in the eye, as well as in the liver (2.8.7). Future directions for this project 
necessarily involve exploring the mechanisms through which therapeutic benefit is conferred. 
Although Nrf2 acts across multiple organ systems, its action is not necessarily identical across 
organ systems. The difference in timecourse of action between AAV-Nrf2-mediated protection 
observed in the liver versus that observed in the eye. As discussed in CHAPTER 2, assessment of 
oxidative stress levels, as well as oxidative damage by immunohistochemical and ELISA 
techniques are necessary to support an antioxidant role for Nrf2 in AAV-Nrf2-mediated 
protection from acetaminophen toxicity. 
However, the timecourse for AAV-Nrf2 mediated rescue from light-induced retinopathy 
occurs on a different time scale from protection seen in acetaminophen hepatotoxicity. As 
previously mentioned, retinal rescue takes place on a timescale of weeks to months. Oxygen 
and nitrogen free radicals are extremely short lived, and have half-lives that are more on the 
time scale of minutes to hours. I would therefore expect an antioxidant-mediated rescue to 
take place on a time scale of hours to days. In order to confirm that the antioxidant defense 
system is not a primary mediator of retinal rescue in these experiments, it is necessary to 
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conduct many of the same assays described in Section 2.7, including the immunohistochemical 
stains for oxidative damage, dihydroethidine assay for detecting levels of oxygen free radicals, 
and protein carbonyl ELISA for protein carbonyl content. 
One difference worth noting between the roles of Nrf2 overexpression in the liver 
model compared to the retina model is that the nature of the different organ systems likely 
plays a big role in the mechanisms behind Nrf2-mediated protection. Although the time course 
of the liver model is indicative of protection from oxidative stress, the liver has known 
regenerative potential and is composed of a relatively homogenous cell type, being mostly 
made up of hepatocytes. The retina on the other hand is a highly structured and differentiated 
organ that is made up of many layers of different cell types. Identifying the cell types 
transduced is a must for any further mechanistic studies. Initial GFP data suggests that Muller 
glia are highly transduced (Figure 3.2), further IHC and colocalization of various cell markers is 
necessary to verify transduced cell types. GFP IHC was done using C57BL/6J mice, likely due to a 
phototoxic response in Balb/C mice (data not shown), a problem that has commonly been 
reported in other systems [161]. IHC could be done on the C57BL/6J sections, or we could also 
look into injecting another vector with a protein that can be stained for. In order to confirm 
AAV-mediated protein expression, AAV2.5-CBh-Luciferase has also been intravitreally injected 
in another cohort of animals to verify expression. This will allow us to validate protein 
expression, but as no good antibodies exist to Luciferase, will not allow us to do IHC to 
determine cell type expression. One interesting future direction for this project would be to 
clone Nrf2 into a variety of different TR plasmids that are under the control of all the different 
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promoters for all retinal cell types. We could then perform light stress and use retinal function 
and structure as a readout for which cell types are the most important for Nrf2 overexpression 
in the context of light damage. 
Although Nrf2 itself was not detectable by western blot (data not shown), downstream 
HO-1 was detectable in retinal lysates from eyes injected with AAV-Nrf2 (Figure 3.2). In order to 
determine the full spectrum of Nrf2-ARE activation, it would be necessary to investigate the 
upregulation of other downstream genes by western blot. In addition to antioxidant genes, it 
would be interesting to evaluate the expression of ARE genes that are involved in cell 
proliferation and differentiation, such as notch. The upregulation of notch and other related 
genes would support a role for AAV-Nrf2-mediated regeneration and proliferation, a 
mechanism that would fit with our observed timeline of rescue from light-induced retinal 
degeneration. 
Further histological analysis could also lend some insight into the possible role of 
proliferation in AAV-Nrf2-mediated retinal rescue. Measurements of specific retinal layers at 
various time points following light damage, in particular the outer nuclear layer, could allow us 
to determine whether cells are dying and then undergoing proliferation. Immunohistochemical 
techniques could be taken advantage of in order to stain for markers of proliferation such as 
Ki67 or BrdU and markers of cell death such as TUNEL or cleaved caspase 3. Staining should be 
done at various time points following light damage, focusing in particular on shorter time points 
within hours to days following light damage, as cell death and proliferation likely initiates at 
short time points and longer time points do not show much staining (data not shown). 
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Studies are currently ongoing to more definitively evaluate the differences between the 
wild-type Nrf2 and the ETGE mutant in vivo. AAV-Nrf2-WT and AAV-Nrf2-ETGE have been 
injected in mice in parallel that have been stressed with light and are currently undergoing 
structural and functional evaluation. Preliminary data suggests that in vivo functional 
differences are not marked (data not shown). However repeat studies utilized a more standard 
5000 lux light stress protocol that did not result in marked rescue of retinal structure or 
function using either wild-type or mutant Nrf2, suggesting that there may be a threshold 
beyond which Nrf2-mediated rescue is no longer therapeutically viable. Indeed, previous 
studies have suggested different mechanisms of degeneration in different protocols of light 
stress [132]. Future studies could further explore the limits of AAV-Nrf2 mediated rescue in a 
variety of different light stress protocols. 
3.7 Experimental procedures 
3.7.1 Virus production and purification 
Nrf2 plasmids were kind gifts from Yue Xiong [110]. Nrf2 was cloned into a single-
stranded AAV TR plasmid backbone under the control of a CBh (mini CBA) promoter [162]. AAV 
was produced, purified, and characterized as previously described [35]. Briefly, AAV was 
produced in HEK293T cells using the triple transfection method and purified on a discontinuous 
iodixanol gradient, followed by ion-exchange chromatography and dialysis. Vector yield was 
assayed using quantitative PCR for viral genomes. 
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3.7.2 SDS-PAGE and Western blotting 
SDS-PAGE and western blotting were performed as previously described (Section 2.8.3). 
One exception is that mouse tissue lysate was prepared differently than cell lysate. Mice were 
euthanized and enucleated, and posterior segments were quickly dissected and either frozen 
on dry ice and stored at -80⁰C for future analysis or immersed in 2x ice cold Passive Lysis Buffer 
(Promega) with protease inhibitor (Halt Protease Inhibitor Cocktail, Life Technologies). Tissue 
was homogenized using a Tissue-Tearor (BioSpec Products) on ice. All subsequent steps were 
performed as previously described (2.8.3). 
3.7.3 Mice 
Balb/C and C57BL/6J mice were purchased from The Jackson Laboratory. Nrf2-/- mice 
were bred and maintained as previously described (2.8.6). Balb/C mice were used for all light 
damage protocols. C57BL/6J and Nrf2-/- mice were used for in vivo expression studies. All mice 
were maintained in UNC animal facilities and all animal experiments were conducted in 
accordance with the policies of the Institutional Animal Care and Use Committee at the 
University of North Carolina at Chapel Hill. Ketamine (75 mg/kg)/Xylazine (10 
mg/kg)/Acepromazine (1.5 mg/kg) was used for anesthesia in all cases where anesthesia was 
required. 
3.7.4 Intravitreal injections 
Animals were anesthetized and pupils dilated with 1% tropicamide and 2.5% 
phenylephrine, and proparacaine-HCl as a local anesthetic. Intraocular needles were 
constructed using 32G cannula with slightly beveled tip and connected with tubing to a 
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Hamilton syringe. Viral suspension was incubated in the intraocular needle at room 
temperature for 10 minutes prior to injection to block the needle from binding virus, then 
evacuated. New viral suspension was drawn up into the needle following blocking, containing a 
small amount of fluorescein sodium salt (Sigma-Aldrich) to confirm successful injection into the 
vitreous cavity as previously described [163]. The intraocular needle was inserted through a 
pilot hole made with a 30G needle to inject into the vitreous under direct observation through 
the microscope. A volume of 1 microliter of 1x109 vector genomes was injected at a constant 
rate over 30 seconds using a syringe pump. The needle was held in place for 20 seconds to 
allow for intraocular pressure equilibration before removal. In mice undergoing light damage, 
one eye was injected with AAV-Nrf2, and the fellow eye was left uninjected to serve as an 
internal control. All injections were carried out by the same surgeon. 
3.7.5 Light damage 
Light damage was performed 6-8 weeks following intravitreal injection of AAV-Nrf2 
according to previously published protocols [125]. Briefly, cages were lined with space blankets 
to maximize reflectivity, and light levels were measured using a handheld luminometer 
carefully adjusted to 4000 lux in each cage by adjusting the height between the light source and 
cage, as well as adding reflective or black backing on the wall behind cages to fine-tune light 
levels. Mice were dark-adapted in a light-tight room 16 hours prior to light exposure. In the 
hour prior to light exposure, mice were dilated under red light with 1% cyclogyl and 5% 
phenylephrine and lights were adjusted. Mice were exposed in separate cages to bright white 
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light for two hours (“moderate light damage”) or three hours (“severe light damage”), then 
allowed to recover in the dark overnight. 
3.7.6 OCT imaging and analysis 
Mice were anesthetized and pupils dilated with 1% tropicamide and 2.5% 
phenylephrine. OCT and retinal fundus images were captured using a Micron IV retinal imaging 
system (Phoenix Research Labs, Pleasanton, CA). Corneas were moistened with Genteal 
lubricant eye gel (Novartis) and positioned with the Micron eyepiece in direct contact with the 
eye through the gel medium. OCT images were captured using the half-scan setting as an 
average of 10 frames per scan. Four scans were taken per eye in the four cardinal directions 
relative to the optic nerve (nasal, temporal, superior, inferior) for analysis. 
Retinal thickness measurements were analyzed using InSight OCT segmentation 
software (Voxeleron). Total retinal thickness was defined as the distance between, and 
including, the ganglion cell layer and the IS/OS junction (Figure 3.4A). 
Retinal pathology scoring was conducted by a scorer who was blinded to the identity of 
scans. Points were given on a scale of 0-2 for any abnormalities in the OPL, OLM, and IS/OS 
junction, as well as the presence of a retinal detachment, as these elements were the easiest to 
quickly identify as disrupted. A score of 0 is indicative of no damage, and 2 is indicative of that 
layer being completely degenerated; in the case of a detachment, 0 is no detachment, and a 1 
or 2 was given to reflect the size of the detachment. Once each image was scored, images were 
unblinded, and each eye was scored as a total of scores from 4 scans, where maximum possible 
score for each scan is 8, and each eye is 32. 
65 
 
3.7.7 Electroretinograms 
ERGs were recorded and analyzed according to previously published protocols [164, 
165]. Briefly, mice were dark adapted overnight and eyes were dilated with 1% tropicamide and 
2.5% phenylephrine under dim red light. Genteal (Novartis) was applied to each eye, and 
recordings were made using gold c-shaped electrodes that were placed gently on the cornea. 
The reference electrode was inserted subcutaneously behind the head, and the ground 
electrode in the tail. ERGs were collected using an Espion E2 system (Diagnosys), and body 
temperature was maintained at 37⁰C throughout the recording. 
A-wave and b-wave amplitudes were determined by processing raw ERG data with 
MATLAB software (version R2014b) as previously described [164]. Briefly, rod-driven a waves 
were measured from the baseline recorded before the flash to the absolute minimum within 
the first 50msec of the recording. Oscillatory potentials were removed from b-wave signals 
using 55 Hz fast Fourier transform low-pass filtering, then taking the absolute peak during the 
time after the first 20msec of the recording and adding it to the absolute value of the a wave.  
3.7.8 Histology 
Mice were euthanized and perfused with PBS containing 1 unit heparin per ml, followed 
by 4% paraformaldehyde in PBS prior to all tissue fixation. 
Animals were sacrificed for histology to evaluate GFP expression 8-12 weeks after 
injection and eyes were prepared for sectioning according to previously described protocols 
[166]. Briefly, eyes were enucleated and a puncture was made anterior to the limbus and eyes 
were incubated in 4% PFA for 10 minutes. Posterior segment eyecups were dissected and 
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placed in 10% sucrose at 4⁰C overnight followed by an additional 30% sucrose overnight 
incubation at 4⁰C. Eyecups were embedded in OCT cutting media (Sakura) and frozen at -80⁰C 
until ready for sectioning. Ten micron transverse cryosections were collected on precleaned 
Superfrost Plus slides (Fisher) and stored at -80⁰C until immunohistochemistry.   
immunostained for GFP. Antibodies used were rabbit anti-GFP (1:500, Millipore) and Alexa 
Fluor 488 goat anti-rabbit (1:1000, Life Technologies). 
For H&E staining, perfused mice were enucleated and whole globes were fixed in 4% 
PFA overnight at 4⁰C. Eyes were then rinsed in PBS at room temperature, then incubated in PBS 
overnight at 4⁰C. Eyes were then placed in 50% ethanol for two hours at room temperature, 
then transferred to 70% ethanol and kept at 4 degrees overnight. Fixed tissues were embedded 
in paraffin and sectioned into 10m sections. Sections were stained with hematoxylin and eosin 
according to conventional staining protocols and imaged using conventional bright field 
microscopy. Paraffin sectioning and H&E staining was carried out by the UNC Center for 
Gastrointestinal Biology and Disease Histology Core Facility. 
3.7.9 Statistics 
For retinal thickness analysis, various sets of curves were compared using the area 
under the curves (AUC). First, the distance axes for all curves were normalized based on the 
greatest minimum and least maximum values. The area under each curve was computed using 
the trapezoid rule. Finally, appropriate non-parametric tests were used to compare the log AUC 
values:  for comparing either the treated or no virus curves to the naïve curves, a Wilcoxon’s 
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rank sum test was used for comparing independent groups; for comparing the treated to no 
virus curves, a Wilcoxon’s signed rank test was used for paired comparisons. 
Statistical significance for retinal pathology scores was assessed using a paired samples 
t-test to compare the retinal pathology scores from AAV-Nrf2-treated eyes vs. uninjected eyes 
from the same animal. 
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3.8 Figures 
 
Figure 3.1. Mechanisms of retinal light damage. 
Phototransduction begins with light absorption by 11-cis retinal, triggering a conformational 
change to all-trans that activates rhodopsin (RR*). (1)Rhodopsin recycling is dependent on 
arrestin and rhodopsin kinase. R* activates the G protein transducin (GG*), which in turn 
activates phosphodiesterase (2). PDE cleaves cGMP (3) to GMP, closing ion channels in normal 
light conditions. (4)Chromophore recycling takes place in the RPE by RPE65. (5)All-trans retinal 
accumulates during excessive light activation and its metabolites result in ROS and RNS. 
(6)Excessive light increases the rate of RPE phagocytosis of outer segments, resulting in ROS 
and RNS. (7)Excessive light results in lipid peroxidation, particularly in outer membrane disks, 
leading to ROS and RNS. (8)Cell damage from ROS and RNS in the outer segment, combined 
with that from the RPE, recruits microglia that phagocytize cell debris and release more free 
radicals. (9)ROS and RNS further activate cGMP, disrupting homeostatic cGMP cycling and 
opening ion channels and resulting in massive Na+ and Ca2+ influx. (10)Increased intracellular 
Ca2+ leads to mitochondrial dysfunction, resulting in further ROS and RNS and further cell death. 
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Figure 3.2. AAV transduction in the retina. 
10m cryosections from mice injected with AAV2-eGFP (A) or AAV2.5-eGFP (B) were 
immunostained for GFP (upper). Both IHC as well as in vivo fluorescent fundus images (lower) 
show increased transduction of AAV2.5-GFP over AAV2-GFP throughout the retina. (C) Western 
blot showing Nrf2 and ARE-controlled gene heme oxygenase 1 (HO-1) expression in Nrf2-/- 
mouse retina lysates from uninjected eyes compared to eyes injected with AAV-Nrf2. Nrf2-/- 
mouse retina lysates were also compared to that from uninjected wild-type mice, as well as 
293T cells untreated or transfected with pAAV-Nrf2. All injections were delivered intravitreally 
into mouse eyes at 1x109 vector genomes in 1l per eye. 
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Figure 3.3. Total retinal thickness following light damage. 
Total retinal thickness was evaluated using OCT in vivo imaging of naïve mouse eyes (yellow, 
n=10) to mice following 3 hours (A-D) or 2 hours (E-H) exposure to 4000 lux of bright white 
light. Prior to light exposure, mice were injected in one eye with AAV-Nrf2 (blue, n=5) and one 
eye was left uninjected (black, n=5). Of eyes exposed to 3 hours of bright light, injected and 
uninjected eyes were compared at 1 week (A, B) and 3 months (C, D, p= 0.0625) following 
exposure. Retinal thickness of naïve mice was also compared to that of eyes 3 months following 
3 hours of light exposure (C, D, p=0.0143). Of eyes exposed to 2 hours of bright light, injected 
and uninjected eyes were compared at 1 week (E, p=0.4375; F, p=0.8125) and 1 month (G, 
p=0.6250; H, p=0.8125) following exposure. Retinal thickness of naïve mice was also compared 
to that of eyes exposed to 2 hours of bright light at 1 week following light exposure (E, p<0.05; 
F, p=0.1416) or 1 month following light exposure (G, black vs. yellow p<0.05, blue vs. yellow 
p=0.3272; H, black vs. yellow p<0.05, blue vs. yellow p=0.05). Individual raw traces of retinal 
thickness (left) and smoothed mean lines (right) are shown, with gray areas representing ± SD 
values for each group. 
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Figure 3.4. Retinal morphology 
following light damage. 
Retinal photomicrographs of H&E 
stained slides from naïve adult 
Balb/C mice (A; D, inset), compared 
to Balb/C mice following exposure to 
bright white light (B, C, E, F). Eyes 
were left uninjected (B; E, inset) or 
injected with AAV-Nrf2 (C; F, inset) 
prior to light exposure. Qualitatively, 
light damage reduces the ONL by 
more than half following light 
damage in regions adjacent to the 
optic nerve (C, F), inner and outer 
segments are almost completely 
degenerated, and the laminar 
ultrastructure of the retina is 
significantly damaged. In contrast, 
AAV-Nrf2 treated retinas (B, E) retain 
a greater ONL thickness, reduced but 
visible inner and outer segments, and 
maintain even laminar retinal layer 
ultrastructure following light 
damage. Scale bar = 200m (A-C). 
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Figure 3.5. Evaluation of retinal pathology by OCT scans 
(A) OCT scan of naïve mouse retina depicting retinal layers on OCT. OCT scans of uninjected and 
AAV-Nrf2-injected mouse retinas 3 months following exposure to severe light damage (B) or 
moderate light damage (C). Corresponding graphs in (B) and (C) depict retinal pathology score 
of uninjected vs. AAV-Nrf2-injected retinas, where scans were blinded and scored for 
pathological features, such as a completely degenerated OPL, OLM, and IS/OS junction (B, left 
arrowhead), OLM not visible (B, right arrowhead), or minor abnormalities in IS/OS junction and 
RPE (C, arrowhead). N=5, (B) p=0.02, (C) p=0.007, paired t-test. scale bars=100m. 
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Figure 3.6. Dark-adapted retinal function following severe light damage. 
ERG recordings and amplitudes showing rod-dominated retinal function 1 week following 
exposure to 5000 lux white light for 2 hours (A, C), or 3 months following exposure to 4000 lux 
white light for 3 hours (B, D). (A, B) Representative traces are shown for injected and uninjected 
eyes. (C, D) Average ERG amplitudes for a (upper) and b (lower) waves were plotted for mice 
exposed to light damage following AAV-Nrf2 intravitreal injection (closed black circles) or left 
uninjected (open circles), compared to age matched naïve mice (yellow circles). Error bars 
represent 2xSEM, n=5 per group, C.I.=95%. 
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Figure 3.7. Dark-adapted retinal function following moderate light damage. 
ERG recordings and amplitudes showing rod-dominated retinal function 1 week (A, C) or 1 
month (B, D) following exposure to 4000 lux white light for 2 hours. (A, B) Representative traces 
are shown for injected and uninjected eyes. (C, D) Average ERG amplitudes for a (upper) and b 
(lower) waves were plotted for mice exposed to light damage following AAV-Nrf2 intravitreal 
injection (closed black circles) or left uninjected (open circles), compared to age matched naïve 
mice (yellow circles). Error bars represent 2xSEM, n=5 per group, C.I.=95%. 
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Figure 3.8. Dark-adapted retinal function in naïve mice. 
ERG recordings show rod-dominated retinal function in mice that have not been exposed to 
light damage. (A) Representative traces are shown for uninjected mice at 2 months and 4 
months of age, as well as for 4-month-old mice that were intravitreally injected with AAV-Nrf2-
WT at 2 months of age. (B) A and b-wave amplitudes are shown for uninjected mice at 2 
months (yellow) and 4 months of age (blue open circles), as well as for 4-month-old mice (blue 
closed circles) that were intravitreally injected with AAV-Nrf2 at 2 months of age. N=5 for all 
groups, error bars indicate ± 2 SEM, C.I. = 95%. 
 
77 
 
   
CHAPTER 4: Breakthroughs and Barriers in Clinical Gene Therapy9 
4.1 Diseases targeted in gene therapy clinical trials 
Over the past two decades gene therapy has begun to make the transition from bench 
to bedside in a wide array of different diseases. By far the greatest number of gene therapy 
clinical trials has been directed toward cancer, perhaps due to sheer prevalence of the disease 
and availability of funding. In stark contrast, the second most common group of diseases for 
which gene therapy clinical trials have been approved are the monogenic diseases, which are 
often rare orphan genetic diseases (Figure 4.1). The Journal of Gene Medicine publishes a 
survey of gene therapy trials worldwide once every few years, and includes a review of the 
distribution of indications for these trials [167-169]. Gene therapy clinical trials for infectious 
diseases, cardiovascular diseases, and neurological diseases are also on the rise, and reviewed 
elsewhere [170-172]. 
In this chapter we review gene therapy clinical trials for the two most studied 
indications in gene therapy clinical trials: cancer, as well as five monogenic diseases – Severe 
Combined Immunodeficiency, Lipoprotein Lipase Deficiency, Leber’s Congenital Amaurosis, 
Cystic Fibrosis, and Hemophilia. Cancer and monogenic diseases were chosen based on the 
large number of gene therapy clinical trials conducted in these two areas to date (Figure 4.1), 
                                                     
9 Reproduced from Advances and Challenges in Delivery of Nucleic Acid Therapeutics. London: Future Science, 
accepted for publication 5 March 2014. Ebook. 
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and certain diseases and trials have been highlighted based on landmark findings they have 
contributed to the field. Severe Combined Immunodeficiency paved the way for gene therapy 
clinical trials in 1990. Gendicine was developed for head and neck cancer and approved for 
clinical use on the Chinese market in 2003. Glybera, developed for Lipoprotein Lipase 
Deficiency, approved by the European Medicines Agency in 2012, is the first gene therapy 
product on the market in the western world. Gene therapy clinical trials for Leber’s Congenital 
Amaurosis have allowed blind patients to see again, trials for cystic fibrosis continue due to high 
demand and funding, if not marked preliminary success, and trials for hemophilia B have saved 
patients millions of dollars in factor IX supplementation costs. Where cancer is highly prevalent, 
monogenic diseases are relatively rare. However, monogenic diseases are particularly suited for 
gene therapy approaches due to the relatively simple nature of a single gene replacement. The 
lessons learned from gene therapy clinical trials in these two categories of diseases provide a 
broad framework upon which future gene therapy clinical trials can build upon in coming years. 
4.2 Cancer 
Cancer has traditionally been the target of the majority of gene therapy clinical trials, 
perhaps due to its wide prevalence [168] and abundance of funding. While enormous effort is 
being made in the gene therapy community to combat cancer, with 1264 trials on record 
accounting for 64.2% of all gene therapy trials to date (Figure 4.1), clear success in this 
endeavor remains elusive. Gene therapy based therapeutics that have come close to market 
approval in the past few years have mostly fallen short, including Cerepro for high-grade glioma 
and TNFerade for pancreatic cancer. In this section, we review a few select areas in cancer gene 
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therapy that have shown the greatest promise in the clinic. For more a more comprehensive 
review of recent developments, please see [173]. 
4.2.1 p53-based therapeutics 
 The majority of late-phase clinical trials currently being conducted for cancer deliver 
variations on the first federally-approved gene therapy product for clinical use, Ad-p53, 
commercially known as Gendicine and approved for head and neck squamous cell carcinoma by 
the State Food and Drug Administration of China in 2003 [174]. The vector used is a replication-
deficient Adenovirus serotype 5 with a deleted E1 region [175]. A second gene therapy product, 
the replication selective oncolytic adenovirus H101, hit the Chinese market in 2006 [176] (See 
CHAPTER 1 Section 1.3 for a detailed review of adenoviruses). China’s rapid move to 
commercialization of gene therapy products has been met with controversy in the gene therapy 
community for lack of adequate phase 3 clinical trial data to sufficiently support its efficacy, 
among other concerns [168, 174, 176, 177]. An equivalent product, Advexin, in the US and 
Europe did not show clear therapeutic efficacy despite extensive clinical trials, and its company 
has since folded [178]. Evidence seems to indicate that Ad-p53 does seem to work in a subset 
of patients [178]; however indications for its use will remain unclear until more rigorous studies 
are done to stratify patients to gene therapy or conventional cancer treatment, perhaps by 
taking into account tumor heterogeneity, both in p53 expression as well as tumor expression of 
viral entry receptors [179]. 
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4.2.2 Suicide Gene Therapy 
 One of the most promising areas in cancer gene therapy to date involves the viral-
mediated delivery of enzymes that metabolize chemotherapy or antiviral prodrugs to minimize 
off-target effects of these drugs, or so-called “suicide gene therapy”. The general approach 
usually involves direct injection of the vector construct into the post-resection tumor bed, 
followed by intravenous infusion of prodrug. One clinical trial investigated the retroviral 
delivery of the Herpes Simplex Virus thymidine kinase gene in conjunction with ganciclovir. 
Ganciclovir is a prodrug antiviral nucleoside analog that requires phosphorylation by viral 
thymidine kinase for DNA incorporation and subsequent blockage of DNA synthesis [180]. 
Despite progressing onto phase 3, this trial did not result in significant improvements in 
survival, likely due to extremely low levels of transduction. A similar phase 1/2 trial is currently 
ongoing using replication-competent retrovirus-mediated delivery of the cytosine deaminase 
gene, a vector called Toca 511, in conjunction with the chemotherapy prodrug 5-fluorocytosine 
(5-FC). Cytosine deaminase converts the inactive 5-FC to the active nucleoside 
chemotherapeutic 5-flurouracil (5-FU). Though trial results have not yet been published, 
preliminary results presented at the 2012 Annual Meeting of the International Society for the 
Cell and Gene Therapy of Cancer from over 30 treated glioma patients indicate positive 
improvements in tumor shrinkage and patient survival [173]. Several improvements were made 
in the Toca 511 trial from the original HSV-TK trials. The HSV-TK trials used a replication-
defective retrovirus, whereas Toca 511 is a replication-competent retrovirus, and seems to 
result in much higher levels of transduction [181] (see CHAPTER 1 Section 1.2 for a detailed 
81 
 
review of retroviruses). Additionally bystander effect, in which activated drug from transduced 
cells is able to spread and exert its effects on neighboring untransduced tumor cells, may be 
more substantial in the Toca 511 trial as 5-FU can freely diffuse among cells, whereas 
ganciclovir cannot. 
4.2.3 Adoptive T cell immunotherapy 
 Adoptive T cell immunotherapy also remains an active area of development for cancer 
gene therapy, reviewed in depth elsewhere [182]. Briefly, this gene therapy strategy employs 
adoptive cell transfer, in which T cells expressing chimeric antigen receptors (CARs) are created 
by genetically engineering a patient’s own T cells to express receptors to recognize tumor-
specific antigens [183]. One approach using CARs to target CD19+ cells to combat B cell 
malignancies has been explored in several recent clinical trials [184-187]. While this therapy 
seems to be effective at eliminating cancerous cells, long-term depletion of normal as well as 
cancerous B cells is an unavoidable side effect. Cytokine storms arising from cellular debris of 
dying cells are another problem, though Carl June showed at the recent European Society for 
Gene and Cell Therapy (ESGCT) 2013 meeting that in recent trials, blocking IL6 has effectively 
shut down these cytokine storms [31]. Approaches employing CARs designed to target other 
tumor-specific antigens have achieved cancer regression in some patients but at the expense of 
serious negative effects on healthy tissues that also unexpectedly expressed the target antigens 
[188, 189]. In one trial, a CAR directed toward a cancer/testis antigen that is expressed in 
several tumor types, as well as healthy testes, resulted in tumor regression in some patients. 
On-target/off-tumor expression was limited in other tissues, promising evidence that the key to 
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this approach relies on identifying suitable target antigens with limited systemic expression 
[190]. At ESGCT 2013, Gianpietro Dotti discussed the promise of targeting well-characterized 
tumor antigens such as EBV and CMV [31]. Loss of tumor antigens can also be a limitation to 
this approach, and Hinrich Abken’s group discussed a possible solution in which inducible IL-12 
is expressed along with the CAR, but only activated upon CAR engagement with antigen, 
triggering an innate immune response against neighboring antigen-loss cancer cell variants [31]. 
Future development of this approach must focus on identifying tumor-specific antigens with 
limited on-target/off-tumor expression, as well as ways to regulate expression to minimize 
long-term off-tumor effects.  
4.2.4 Further considerations for cancer gene therapy 
 The choice of vector remains one of the largest considerations in the field of cancer 
gene therapy. Where many clinical trials value adenovirus for its cytolytic capabilities, in other 
applications retroviral vectors are necessary for their integrative capacity, in particular where 
the strategy involves adoptive cell transfer. Replication-competent retroviruses also seem to 
add additional benefits in the suicide gene therapy approach by allowing increased 
transduction capacity necessary for sufficient enzyme expression. Recent developments in 
oncolytic viruses, including Celyvir (Adenovirus), ColoAd1 (Adenovirus), and an oncolytic 
parvovirus were recently discussed at the ESGCT 2013 with great enthusiasm [31]. For a 
detailed review of developments in viral constructs, refer to CHAPTER 1. 
The evaluation of clinical outcomes in cancer gene therapy involves a number of 
different considerations when compared to the evaluation of gene therapy for monogenic 
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diseases, discussed in the following section. Many of these trials involve patients with late-
stage or refractory cancer whose options are limited or nonexistent. Survival estimates for 
these patients are often counted in months, if not weeks. In these scenarios it may be 
reasonable to consider a higher risk threshold in the evaluation of possible therapeutics. 
Although several of the clinical trials discussed above involve patient deaths, it is always 
necessary to consider the outcomes for similar patients on conventional therapy in these 
situations. 
4.3 Monogenic Diseases 
 Many monogenic diseases are at a loss when it comes to standard of care; often gene 
therapy is the most promising therapeutic currently in the pipeline. While there has been a 
focus on orphan heritable diseases due to the lack of adequate alternatives, as well as the 
straightforward rationale of direct gene replacement, their rarity poses a large concern. In 
addition to the huge resources spent on a small number of patients, the small number of 
patients itself is a barrier to performing large scale phase 3 clinical trials to validate efficacy, as 
seen in the next section with gene therapy clinical trials for Lipoprotein Lipase Deficiency. 
Nevertheless, gene therapy trials for monogenic diseases have been excellent proof-of-principle 
opportunities for the field, and have contributed invaluable information about safety and 
efficacy of gene therapy approaches in the clinical setting. 
In this section we will review landmark successes in gene therapy for monogenic 
diseases, including clinical trials for SCID, Lipoprotein Lipase Deficiency, Leber’s Congenital 
Amaurosis, Cystic Fibrosis, and Hemophilia. Whereas cyotolytic and replication-competent 
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viruses are often necessary to eradicate aggressive malignancies, monogenic diseases are 
usually the result of loss-of-function mutations that require careful gene replacement and 
preservation of healthy tissue. As we will discuss in the following sections, the need for an 
elevated safety profile outside of the world of cancer has pushed the field forward in the 
development of new generations of viral vectors that maintain high transduction profiles while 
decreasing cytotoxicity, antigenicity, integration, and replication. For an in-depth review of 
progress in vector development over the years, see CHAPTER 1. 
4.3.1 Severe combined immunodeficiency 
Severe combined immunodeficiency (SCID) paved the way for human gene therapy in 
1990, when the first therapeutic gene was administered to humans [3, 191], followed by the 
first clinically successful gene therapy a decade later [192]. SCID is a rare heritable disease of 
impaired immune system development caused by a heterogeneous group of genetic deficits 
that affect T and B cell development and maturation. When left untreated, patients die from 
overwhelming infection within the first year of life [193]. X-linked (X1) and Adenosine 
Deaminase (ADA) SCID are the two most common SCID subtypes, accounting for approximately 
50% and 15% of total SCID cases, respectively [193, 194]. ADA-SCID is caused by mutations in 
adenosine deaminase, an enzyme that is highly abundant in erythrocyte and lymphocyte 
precursors and plays an important role in purine metabolism. In addition to causing 
immunological deficits, metabolic dysfunction also results from toxic purine metabolites in the 
bloodstream [195]. SCID-X1 is caused by a mutation in the common cytokine receptor gamma-
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chain (c) [196, 197], a component of a large family of cytokine receptors responsible for 
lymphocyte development [198]. 
Current standard of care is hematopoietic cell transplantation (HCT) when appropriate 
donors are available [193]. Two to three-year survival for HCT in SCID patients is currently high 
(≥90%) when using related HLA-matched donors, and if successful, HCT is a potentially curative 
treatment option. However, HLA-matched related donors are unavailable to most patients. 
Corresponding survival for HCT using HLA-matched unrelated donors remains at 69-80%, and 
unmatched related donors at 52-66%, with graft-vs-host disease being the major cause of 
complications [199-201]. While ADA-SCID patients may have the option of enzyme replacement 
therapy (ERT) using PEG-ADA treatment (reviewed elsewhere [202]), this requires weekly 
injections [203], is extremely expensive, and results in incomplete immune function that 
declines over time [204]. ERT is not an option for SCID-X1 patients [205]. 
Gene therapy developments over the last decade have demonstrated a promising 
alternative for both SCID-X1 and ADA-SCID patients lacking related HLA-matched donors [206]. 
Gene therapy for SCID has focused on adoptive cell transfer of gene-corrected hematopoietic 
stem cells (HSC). In order to achieve this task, retroviral-mediated integration of the corrected 
gene into host HSCs is necessary for stable expression of the corrected gene in subsequent 
progeny throughout lymphoid development [19]. 
Severe combined immunodeficiency (SCID) paved the way for human gene therapy in 
1990, when the first therapeutic gene was administered to humans [3, 191], followed by the 
first clinically successful gene therapy a decade later [192]. SCID is a rare heritable disease of 
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impaired immune system development caused by a heterogeneous group of genetic deficits 
that affect T and B cell development and maturation. When left untreated, patients die from 
overwhelming infection within the first year of life [193]. X-linked (X1) and Adenosine 
Deaminase (ADA) SCID are the two most common SCID subtypes, accounting for approximately 
50% and 15% of total SCID cases, respectively [193, 194]. ADA-SCID is caused by mutations in 
adenosine deaminase, an enzyme that is highly abundant in erythrocyte and lymphocyte 
precursors and plays an important role in purine metabolism. In addition to causing 
immunological deficits, metabolic dysfunction also results from toxic purine metabolites in the 
bloodstream [195]. SCID-X1 is caused by a mutation in the common cytokine receptor gamma-
chain (c) [196, 197], a component of a large family of cytokine receptors responsible for 
lymphocyte development [198].  
Current standard of care is hematopoietic cell transplantation (HCT) when appropriate 
donors are available [193]. Two to three-year survival for HCT in SCID patients is currently high 
(≥90%) when using related HLA-matched donors, and if successful, HCT is a potentially curative 
treatment option. However, HLA-matched related donors are unavailable to most patients. 
Corresponding survival for HCT using HLA-matched unrelated donors remains at 69-80%, and 
unmatched related donors at 52-66%, with graft-vs-host disease being the major cause of 
complications [199-201]. While ADA-SCID patients may have the option of enzyme replacement 
therapy (ERT) using PEG-ADA treatment (reviewed elsewhere [202]), this requires weekly 
injections [203], is extremely expensive, and results in incomplete immune function that 
declines over time [204]. ERT is not an option for SCID-X1 patients [205]. 
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Gene therapy developments over the last decade have demonstrated a promising 
alternative for both SCID-X1 and ADA-SCID patients lacking related HLA-matched donors [206]. 
Gene therapy for SCID has focused on adoptive cell transfer of gene-corrected hematopoietic 
stem cells (HSC). In order to achieve this task, retroviral-mediated integration of the corrected 
gene into host HSCs is necessary for stable expression of the corrected gene in subsequent 
progeny throughout lymphoid development [19]. 
4.3.1.1 ADA-SCID 
 Gene therapy clinical trials for ADA-SCID initiated in 1990 marked the first time 
therapeutic genes were introduced into humans. However, clinical success was limited due to 
low levels of expression [207], or uncertain due to difficulty in determining the effect of gene 
therapy due to concurrent coadministration of PEG-ADA [191, 208]. More recently, three Phase 
1/2 gene therapy clinical trials for ADA-SCID have reported significant long-term clinical success 
(Table 4.1) [209-211]. In these trials, a gammaretroviral vector was used to transduce the 
patient’s own CD34+ stem cells with the human ADA gene. Immune reconstitution as well as 
metabolic reconstitution, evaluated by differential lymphocyte count and ADA enzyme 
activity/purine metabolite levels respectively, were restored in over half of all trial patients to 
levels at which ERT was no longer needed [209-211]. In cases where gene therapy was 
ineffective, failure of HSC gene therapy could often be attributed to one of several factors: 
1. Concurrent ADA-PEG administration may prevent selection of transduced HSCs. The 
need to withdraw ADA-PEG prior to adoptive transfer to allow for selective advantage of 
gene-corrected cells [210, 212], is reviewed in depth [213]. While conflicting evidence 
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exists regarding ERT post-transplantation, the most recent evidence suggests that ERT 
post-transplant may actually aid engraftment of gene-corrected cells. 
2. The necessity of myelosuppressive conditioning to promote transplant engraftment is 
also reviewed in depth [213]. Patients who did not receive myelosuppressive 
conditioning and remained on ADA-PEG had extremely low counts of ADA-positive 
transduced cells post-gene therapy [210]. 
3. The rationale for better outcomes in younger patients vs. older patients is discussed 
[210]. One explanation is that older patients had lower CD34+ cell counts available for 
gene transfer, such that the total number of gene-corrected cells was lower, which may 
have contributed to poor engraftment efficiency. 
4.3.1.2 SCID-X1 
Trials for SCID-X1 marked the first clinically success in gene therapy when initial results 
of two SCID-X1 patients were published in 2000 [192]. This initial publication has since been 
bolstered by longer follow-ups with more patients [214-216], and even a similar independent 
trial [217] (Table 4.2). One consideration in the treatment of SCID-X1 is the age of the patient. 
Failure of gene therapy to correct disease has been reported in two older SCID-X1 patients 
despite successful gene transfer to CD34+ cells [218]. Evidence that age-related changes in 
thymopoiesis may limit the therapeutic time window of HCT transplantation is discussed in 
depth elsewhere [218]. 
 Unfortunately, progress in SCID-X1 clinical trials has been hampered by insertional 
mutagenesis, with several patients in two independent trials developing T cell acute 
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lymphoblastic leukemia (T-ALL) and even one death [219, 220]. Interestingly, no ADA-SCID trial 
patients have developed T-ALL, despite the use of similar vector constructs. The explanation for 
the disparity remains unclear; however several hypotheses have been discussed surrounding 
the nature of the two transgenes being inherently different, as c is a proliferative signal and 
ADA is a housekeeping gene responsible for purine metabolism. These issues are reviewed in 
depth elsewhere [221]. Briefly: 
1. The proliferative signal from newly introduced c results in rapid lymphoid expansion, 
possibly increasing risk for mutagenesis. Lymphocytes in post-transplantation ADA-SCID 
follow a slower recovery course. 
2. The c gene product itself provides absolute selective advantage. Only cells carrying the 
corrected transgene survive, creating selective proliferative pressure for transduced 
cells and the development of a dominant clone. On the other hand, a heterogeneous 
population of corrected and uncorrected HSCs are used in ADA-SCID, with corrected 
cells offering some cross-correction activity to uncorrected cells. 
3. c itself may act synergistically with proto-oncogenes activated by insertional 
mutagenesis to tip the scale toward uncontrolled proliferation, whereas even if a similar 
event does happen during the treatment course of ADA-SCID, it may not be sufficient to 
result in cancer. 
4. The SCID-X1 background itself may predispose toward insertional mutagenesis [222]. 
Evidence suggests that gammaretrovirus is associated with skewed integration sites [223], 
limiting its use for SCID-X1, in which the conditions described above create a perfect storm for 
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insertional mutagenesis and subsequent uncontrolled T cell proliferation. To minimize risk of 
oncogene activation from insertional mutagenesis, self-inactivating (SIN) gammaretroviruses 
have been optimized for use in SCID-X1 specifically [15]. SIN vectors contain a deletion in the 3’ 
LTR and the insertion of an internal promoter, reducing the potent viral promoter and enhancer 
activity of the LTRs and therefore the risks of unintended activation of genes surrounding the 
insertion site. For details regarding the development of self-inactivating vectors, see section 1.2 
on retroviruses in CHAPTER 1. 
4.3.2 Lipoprotein Lipase Deficiency 
 Gene therapy for Lipoprotein Lipase Deficiency (LPLD) was approved by the European 
Medicines Agency (EMA) in 2012, making it the first clinically approved gene therapeutic in the 
western world. Where Gendicine’s move to commercialization was largely ignored (see section 
4.2 on cancer), Glybera has been largely heralded in gene therapy community as a landmark 
success [224, 225]. LPLD is a rare autosomal recessive disorder causing insufficient production 
of lipoprotein lipase needed to catalyze the breakdown of lipoproteins [226]. The buildup of 
triglycerides caused by LPLD has been linked to chylomicronemia, hypertriglyceridemia, and 
potentially fatal complications such as chronic pancreatitis [227]. Current standard of care is a 
strict low-fat diet supplemented with medium-chain fatty acids to minimize postprandial 
chylomicron formation and decrease circulating chylomicron levels. Although LPLD is not 
associated with high mortality and patients can lead a fairly normal life with proper diet 
restriction, diet modification does not eliminate the risk of pancreatitis or affect disease 
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progression, and patient response is variable. Glybera (alipogene tiparvovec) is a pseudotyped10 
AAV2/1 capsid carrying a gain-of-function LPL transgene in an AAV2 DNA backbone. The goal of 
gene therapy, combined with reduced fat intake, is to further limit complications associated 
with LPLD [228-231]. 
Two LPLD trials have been conducted using AAV1 capsids, a serotype with higher muscle 
tropism than AAV2 [74, 232], to deliver the human gain-of-function LPL gene via intramuscular 
injection (Table 4.3) [63, 229, 233]. Nearly all patients achieved the primary outcome measure 
of a decrease in triglyceride levels. Although triglyceride levels returned to baseline after a few 
weeks, overall pancreatitis incidence decreased by five-fold in one trial [63], and the therapy 
was well tolerated for two years with persistent LPL gene expression. Although AAV1 has 
slightly lower seroprevalence than AAV2 [37], return of triglyceride levels to baseline was 
hypothesized to be related to cell-mediated immune rejection of transduced cells [63]. 
Nevertheless trial results were promising, with many patients experiencing long-lasting 
improvements including increased energy levels, increased food tolerance, and improved 
abdominal comfort [63]. This was the first instance of a gene therapy treatment leading to 
persistent gene expression and long-term clinical benefits for a systemic disorder [63, 229, 
233].  
                                                     
10 Pseudotyping refers to a viral genome from serotype being packaged into the capsid of an alternate serotype. All 
clinical use of AAV contains DNA constructs based on the AAV2 genome, but may be pseudotyped with other 
capsids. The terminology where both capsid and genome is indicated continues to be used, but is decreasing in 
popularity. For example, AAV2/1 indicates an AAV2 genome packaged inside an AAV1 capsid. However, many 
groups are moving to the less cumbersome format of indicating the capsid only, where it is assumed that the 
genome is derived from AAV2 unless otherwise indicated. 
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The approval process for commercialization of Glybera has brought up some notable 
points for consideration of future gene therapy products. Despite the small patient numbers 
recruited to clinical trials due to the rarity LPLD, Amsterdam Molecular Therapeutics (AMT) 
submitted an application for Glybera marketing approval to the EMA in January 2010. Citing 
insufficient evidence for clinical relevance due to the small number of patients, the Committee 
on Human Medicinal Products (CHMP) initially rejected marketing authorization in 2011. With 
persistent lobbying and political persuasion, CHMP reconsidered AMT’s application and granted 
marketing authorization in 2012 recognizing the “the difficulty of obtaining data in this rare 
disease” and the lack of available effective treatments for LPLD [1]. This instance raises the 
question of how to integrate gene therapy treatments for orphan diseases into mainstream 
medicine. The struggle to obtain approval for Glybera will likely streamline the approval process 
for future gene therapy treatments. 
4.3.3 Leber’s Congenital Amaurosis 
 Leber’s Congenital Amaurosis (LCA) is a rare heterogeneous group of inherited retinal 
diseases that result in incurable congenital blindness [234, 235]. To date, mutations in 15 genes 
have been associated with LCA [236], though the diagnosis remains largely a clinical one. Three 
separate gene therapy clinical trials for LCA were launched in 2007 [149, 150, 237]. In all three 
trials, AAV2 was used to deliver RPE65, a gene that corresponds to one of the more common 
causative mutations (~6% of cases) [235], via subretinal injection. RPE65 is an enzyme located 
in the retinal pigment epithelium that recycles the photopigment critical to the visual cycle 
93 
 
[236]. The unprecedented clinical efficacy seen in these trials has launched this heritable 
retinopathy into the spotlight as a poster child for success in the gene therapy community. 
All three clinical trials initially started with three patients each and improvements in visual 
function in some capacity were seen in all trials (Table 4.4). At least half of patients in both 
Philadelphia-based trials experienced improvements in pupillary reflex, visual field, visual 
sensitivity, and visual mobility [149-151, 238-242]. The two Philadelphia-based trials have since 
recruited more patients and continued following patient progress over multiple years, and the 
Philadelphia/Naples trial has now advanced on to Phase 3. The success from the original clinical 
trials has prompted the initiation of at least three additional clinical trials in three different 
countries (NCT00749957, NCT00821340, NCT01496040 – Clinicaltrials.gov). 
Several factors may account for disparities in patient outcomes observed from trial to 
trial (Table 4.4). Firstly, the vector promoter and dosage (both titer and volume) was different 
across all three trials. Patient outcomes at the highest dose seemed to be slightly worse than 
low and medium doses, likely due to a larger injection volume resulting in a greater retinal 
detachment, rather than the larger vector dose [242]. Whether age has an effect on magnitude 
of improvement continues to be disputed [238, 242]. Patients with worse pretreatment visual 
acuity also tended to have greater improvements. Interestingly, this was attributed to the fact 
that the most impaired patients often had significant nystagmus, an involuntary eye movement 
that interfered with visual testing, that improved post-therapy [243]. Ongoing trials will attempt 
to use genotype-phenotype correlations to guide treatment strategy, as well as optimize the 
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site of injection (foveal vs. extrafoveal), a point of contention at the time of publication of most 
recent manuscripts [239, 242]. 
4.3.4 Cystic Fibrosis 
Cystic Fibrosis (CF) is the most common potentially fatal autosomal recessive disease in 
Caucasians, with 1 in 25 individuals carrying the heterozygous genotype [244-246]. Over 1,300 
causative mutations have been discovered in the Cystic Fibrosis transmembrane conductance 
regulator (CFTR) gene, which encodes a cAMP-regulated chloride ion channel. CFTR also acts as 
a cAMP-dependent negative regulator of sodium ion channels, effectively balancing sodium 
absorption and chloride secretion to properly hydrate airway epithelium secretions [247, 248]. 
Current standard of care for CF addresses sinus infection, nutritional status, and glucose 
control. Pharmacological treatments include antibiotics, bronchodilators, and agents to 
promote sputum clearance. Other treatments include chest physiotherapy, supplemental 
oxygen, and noninvasive positive pressure ventilation. In cases of advanced CF lung disease, 
lung transplantation improves survival rates of CF patients [249]. The median life expectancy of 
CF patients in the United States is roughly 37 years [250]. 
Early gene therapy CF clinical trials used Ad2 to deliver wild-type CFTR into nasal and 
bronchial epithelial cells. Researchers observed a transient increase in nasal potential 
difference (NPD), a measure of the voltage across the nasal epithelium, from the typically 
electronegative voltages of CF patients, demonstrating safety and clinical efficacy [251-253]. 
However, these trials were hampered by lack of long-term gene expression [252-259], and 
repeat administration was ineffective due to immune response to the vector capsid [255, 257]. 
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Hoping to increase gene expression and decrease the immune responses to vectors, 
researchers turned to AAV vectors. AAV2 was used to deliver the wild type CFTR to the 
maxillary sinus epithelium in three phase 1/2 trials (Table 4.5). Researchers observed safe and 
effective gene transfer, [260-263], but only one trial observed much clinical success [264]. 
Repeat administration did not result in clinical improvement, perhaps related to viral shedding 
and increased production of neutralizing antibodies observed after each administration [264]. 
Gene therapy efficacy in CF trials in particular seems to be hindered by low levels of 
transduction (For a review of strategies to increase transduction efficiency see CHAPTER 1). As 
evidenced by these clinical trials, AAV2 does not sufficiently transduce human airway epithelial 
cells; however, selection of an appropriate AAV capsid to increase tropism has been hindered 
by the species-specific nature of AAV airway transduction [265]. As more AAV capsids are 
approved for use in clinical trials, exploration of other capsids or alternate delivery vectors may 
be useful to maximize tropism for target organs, increase transduction efficiency, and minimize 
systemic spread [266, 267]. Researchers have also explored use of stronger promoters to 
increase expression levels, though solutions must overcome the large CFTR cDNA and small 
AAV packaging size. Promising developments include constructs that involve trans-splicing and 
homologous recombination [268, 269], as well as shortening of the CFTR construct [270-272]. 
The future of CF gene therapy will focus on strategies for increasing longevity and strength of 
gene expression, and devising new methods of quantifying efficacy of gene transfer for future 
clinical trials. 
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4.3.5 Hemophilia 
Hemophilia B is a rare X-linked recessive bleeding disorder that can be caused by a 
variety of transposition, substitution, deletion, and inversion mutations in the Factor IX (FIX) 
clotting factor gene [273]. Current standard of care for hemophilia B involves recurrent 
administration of FIX concentrates once daily to prevent bleeding and resolve existing 
hemorrhage [274]. Hemophilia B gene therapy clinical trials are a promising alternative to the 
expensive and limiting lifestyle required for constant FIX administration. 
Clinical trials for hemophilia B have successfully paved the way for several new AAV 
developments in the clinic, including the use of a pseudotyped AAV2/8 vector and a self-
complementary (sc) transgene cassette (For an in-depth discussion of the development of novel 
AAV constructs, see CHAPTER 1). Three clinical trials have shown safety of AAV-mediated gene 
transfer of the FIX in hemophilia B patients (Table 4.6). In the first of these trials, intramuscular 
delivery of AAV2-FIX resulted in long-term expression [275], but failed to reach therapeutic 
levels of circulating FIX in humans [276]. A transvenular administration approach was later 
explored in transgenic hemophilia B dogs, and resulted in long-term clinical correction [277]. 
Another trial used intravenous delivery to achieve therapeutic levels of FIX, though benefits 
were short-lived due to cell-mediated immunity against AAV2 capsid antigens causing 
destruction of transduced hepatocytes [278]. A third trial used scAAV8 vectors in an attempt to 
circumvent immune response issues, reducing potential immunogenicity due to lower 
seroprevalence of AAV8, as well as a possibility of decreasing vector dosage because of 
increased transduction efficiency of sc vectors [279]. Patients experienced long-term expression 
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of FIX at therapeutic levels without toxicity, although AAV8 capsid-specific T-cell responses 
increased with dose [50]. In the recent ESGCT update of three-year patient outcomes, Amit 
Nathwani reported that expression levels in this trial remain high enough to eliminate the use 
of supplemental FIX on a regular basis for most patients, a financial benefit as well as a clinical 
one, as ~1.5 million saved from FIX costs has essentially made the trials pay for themselves [31]. 
4.3.6 Monogenic diseases: Looking ahead 
Gene therapy approaches using retroviral vectors to correct hematopoetic stem cells 
have been remarkably successful in terms of clinical efficacy. Though trials for SCID-X1 in 
particular were confronted with the dangers of insertional mutagenesis, great progress is being 
made to design safer vectors while maintaining efficiency. In addition to SCID, trials for 
Wiskcott-Aldrich Syndrome, Chronic Granulomatous Disease, -thalassemia, and X-linked 
adrenoleukodystrophy have also shown a lot of recent success [224, 280]. Of note, several 
centers in Europe and the US have recently joined in an international effort to push ahead 
clinical protocols to treat rare primary immunodeficiencies using adoptive cell transfer of gene-
corrected cells, as described by Anne Galy at the recent ESGCT 2013 meeting [31]. The strategy 
employs SIN lentiviral vectors for gene transfer, and preliminary clinical results from this effort 
suggest the vectors are safe and effective. The urgency with which this effort has been pushed 
forward will hopefully result in the application of viral vectors optimized for safety in what is 
already a promising field of gene therapy for primary immunodeficiency disorders. 
Gene therapy for monogenic diseases as reached its heyday with the explosion of AAV 
vector development. In addition to the success of the LCA and hemophilia B trials, recent 
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success has also been achieved in gene therapy clinical trials for Parkinson’s disease [281]. At 
ESGCT 2013, Thomas Voit’s group showed that gene therapy was successful in treating a large 
cohort of Golden Retriever Muscular Dystrophy dogs. AAV8 was used to carry a modified 
U7snRNA sequence promoting exon skipping, restoring a shorter and functional dystrophin 
sequence [31]. AAV technology, including the engineering of self-complementary vectors and 
pseudotyped vectors should propel the progress of gene therapy for the treatment of 
monogenic diseases forward for years to come. 
4.4 Conclusions 
 Serious adverse events involving insertional mutagenesis prompted much discussion in 
the gene therapy community about regulatory issues and risk/benefit assessment to guide the 
approval process for gene therapy clinical trials. In addition to successful clinical outcomes, 
other factors drive development of clinical gene therapy, as seen with cancer and CF – although 
gene therapy clinical trials haven’t been wildly successful, gene therapy trials will continue 
because of high prevalence and funding. Gene therapeutics for cancer and LPLD have paved the 
way for gene therapy market approval, and shed light on the regulatory process for novel 
therapeutics that will be useful for future gene therapeutics seeking to enter 
commercialization. Lessons learned from gene therapy for monogenic diseases provide a 
platform on which to build vector administration protocols for more complex, multifactorial 
diseases. Evidence suggests that gene therapy may be more effective in younger patients, as 
seen in the clinical trials for SCID and LCA. Future development of clinical gene therapy will be 
driven and dictated by the development of safer and more efficient viral vectors. 
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4.5 Figures and Tables 
 
Figure 4.1. Cancer and monogenic lead the way amongst indications addressed by gene 
therapy clinical trials worldwide. 
Numbers account for gene therapy clinical trials approved/initiated between 1989-2013 
Reproduced with permission from [169] © Wiley 2013. 
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Table 4.1. ADA-SCID Gene Therapy Clinical Trials 
 
 
 
 
ClinicalTrials.gov ID NCT00599781 (Phase 
1/2) 
NCT00598481 (Phase 2) 
NCT00018018 (Phase 1) 
NCT00794508 (Phase 2) 
n/a 
Published results [209, 282-285] [210] [211, 286] 
Location Hadassah University 
Hospital, Israel/ San 
Raffaele Scientific 
Institute, Italy/ 
GlaxoSmithKline 
NIH/CC/NHGRI 
Bethesda, MD, USA 
University College, 
London, UK 
Status Phase 1 completed 
Phase 2 active 
Active Unknown 
# Patients (range of ages 
at time of treatment) 
11 patients (0.6-5.6yo) 10 patients (1-20yo) 6 patients (0.5-3yo) 
Median follow-up 
(range) 
4 years (1.8-8 yrs) 5 years (2.5-10 yrs) 4.5 years (2-7 yrs) 
Vector MLV-based 
gammaretrovirus 
targeting CD34+ 
MLV-based 
gammaretrovirus 
targeting CD34+  
Gammaretrovirus 
targeting CD34+ 
PEG-ADA Discontinued 3 weeks 
prior to gene therapy 
Group 1 (4 patients) 
continued on PEG-ADA 
Group 2 (6 patients) 
discontinued 1-2 weeks 
prior to bone marrow 
harvest 
Discontinued 1-4 weeks 
prior to bone marrow 
harvest 
Myelosuppressive 
conditioning 
Busulfan Group 1: none 
Group 2: Busulfan 
Melphalan, Busulfan (1 
pt) 
Clinical outcomes: 
Immune reconstitution 
Off ERT – 8/10 
Off IVIg – 5/10 
Mostly below normal 
range 
Group 1: similar to long 
term ADA-PEG 
Group 2: Off ERT – 3/6 
Off IVIg – 1/6 
Off ERT – 4/6 
Off IVIg – 3/6 
Clinical outcomes: 
Metabolic reconstitution 
measured by erythrocyte 
ADA activity (# patients) 
↑ (all patients off ERT) Group 1: none 
Group 2: ↑ (6/6) 
↑ (3/6 patients) 
Noteable adverse events 
(# patients) 
Autoimmune – 2/10 
Prolonged 
thrombocytopenia/ 
neutropenia – 2/10 
Self-limited rise in liver 
enzymes in 2/6 patients 
from Group 2 
n/a 
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Table 4.2. SCID-X1 Gene Therapy Clinical Trials 
ClinicalTrials.gov ID NCT01410019 NCT01175239 
Published results [192, 214, 215, 219, 287] [211, 217, 220] 
Location Laboratoire de Thérapie Cellulaire et 
Génique/ Hôpital Necker Enfants Malades, 
Paris, France 
University College/ Great Ormond Street 
Hospital NHS Trust, London, UK 
Status Phase 1/2 Phase 1/2 
# Patients (range of ages 
at time of treatment) 
9 patients(1-11 mo) 4 patients (4-33 mo) 
Median follow-up 
(range) 
9 years (8-11 yrs) 2 years (1-2.5 yrs) 
Vector MLV-based gammaretrovirus Pseudotyped MLV-based gammaretrovirus 
Clinical outcomes (# 
patients) 
Off IVIg – 5/7 
Normal T cell counts: 
CD3+: 6/7, CD4+: 4/7, CD8+: 7/7 
Normal Ig counts: 
IgG: 3/7, IgA: 4/7, IgM: 5/7 
Off IVIg – 2/4 
Normal Ig counts: 
IgG: 1/4, IgA: 2/4, IgM: 2/4 
Noteable adverse events 
(# patients) 
4/9 developed T-ALL 
1/9 death 
1/10 patients developed T-ALL 
 
 
Table 4.3. Lipoprotein Lipase Deficiency Gene Therapy Clinical Trials 
ClinicalTrials.gov ID NCT01109498 NCT00891306 
Published results [63]  [233] [229] 
Location Amsterdam Molecular Therapeutics, 
Netherlands 
Ecogene-21 Clinical Trial Center/ Centre 
de santé et de services sociaux de 
Chicoutimi, Quebec, Canada 
Status Phase 2 Phase 2/3 
# Patients (range of ages 
at time of treatment) 
Cohort 1: 4 patients (mean age 44 yo) 
Cohort 2: 4 patients (mean age 52 yo) 
Phase 1: 14 patients (28-60 yo) 
Phase 2: 5 patients (20-57 yo) 
Follow-up range 18-31 months  Phase 1: 2 years 
Phase 2: 14 weeks 
Vector/promoter AAV1/CMV AAV1/CMV 
Dose (vector 
genomes/kg) 
1x1011 (Cohort 1) 
3x1011 (Cohort 2) 
Phase 1: 3x1011 (n=6), 1x1012 (n=8) 
Phase 2: 1x1012 
Route of administration intramuscular intramuscular 
Clinical outcomes: 
Triglyceride levels 
(# patients) 
All ↓ 
3/8 ↓ > 40% 
All returned to baseline by final follow-up 
Phase 1: 12/14 ↓, 7/14 ↓ >40% 
Phase 2: 4/5 ↓ at 14 weeks 
All returned to baseline by final follow-up 
Notable adverse events None None 
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Table 4.4. Leber’s Congenital Amaurosis Gene Therapy Clinical Trials 
ClinicalTrials.gov ID NCT00481546 NCT00516477 (Phase 1) 
NCT01208389 (Phase 2) 
NCT00999609 (Phase 3) 
NCT00643747 
Published results [149, 240-242] [150, 151, 238, 239] [288] 
Location Scheie Eye Institute, 
University of 
Pennsylvania/ Shands 
Children's Hospital, 
University of Florida, USA 
Children's Hospital of 
Philadelphia, USA/ 
Seconda Università degli 
Studi di 
Napoli, Italy 
Moorfields Eye Hospital 
NHS Foundation Trust, 
London, UK 
Status Phase 1, still active Phase 1/2, still active 
Phase 3 initiated 
Terminated 
 
# Patients (range of ages 
at time of treatment) 
15 patients (11-30 yo) 12 patients (8-44 yo) 3 patients (17-23 yo) 
Median follow-up 
(range) 
18 months (1-36 mos) 3 years (2-4 yrs) 12 months (6-12 mos) 
Vector/Promoter AAV2/CBA AAV2/CBA with modified 
Kozak translational 
initiation sequence 
AAV2/hRPE65 fragment 
Dose (vector genomes) 5.96x1010 – 1.79x1011 
 
1.5×1010 - 1.5×1011  Up to 1×1011 
Route of administration 
(Injection volume) 
Subretinal (150 - 450mL) Subretinal (150 - 300mL) Subretinal (Up to 1mL) 
Clinical outcomes: Visual 
acuity (# patients) 
Some improvement, but 
difficult to parse out 
learning effects, p = 0.05 
(study eye) vs 0.02 
(control eye)  
8/12 improved,:  
Low dose – 3/3 
Med dose – 3/6 
High dose – 1/3 
No improvement 
 
Clinical outcomes: Visual 
sensitivity ↑(# patients) 
15/15 5/7 (Full field stimulus 
test) 
1/3 (Perimetry) 
Clinical outcomes: Visual 
mobility ↑(# patients) 
3/6 7/12 1/3 
Clinical outcomes: Visual 
field ↑(# patients) 
11/12 12/12 1/3 
Clinical outcomes: 
Pupillary reflex ↑(# 
patients) 
14/14 11/11 n/a 
Notable Adverse events 
(# patients) 
Foveal thinning(1 pt) Macular hole (1 pt) 
Pigment atrophy(1 pt) 
None 
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Table 4.5. Cystic Fibrosis AAV Gene Therapy Clinical Trials 
Published 
results 
[260] (Phase 1) 
[261] (Phase 2) 
[262] (Phase 1) 
[264] (Phase 2) 
[263] (Phase 1) 
 
Location Stanford University, USA University of Washington, 
USA 
University of Florida, USA 
# Patients 
(range of ages 
at time of 
treatment) 
 
Phase 1: 10 patients (20-38 
yo) 
Phase 2: 23 patients (n/a) 
Phase 1: 12 patients (19-41 
yo) 
 Phase 2: 37 patients (n/a) 
25 patients (15-43 yo) 
Follow-up range 3 months 150 days 6-24 months 
Vector AAV2 AAV2 AAV2 
    
Dose (vector 
genomes)  
Phase 1:1x102 - 1x105 per 
dose, 1-2 doses. 
Phase 2: 1x105 RU 
Phase 1: 1010 - 1013  
Phase 2: 1x1013 , 3 doses 
3x101 - 1x109  
Route of 
administration 
Maxillary sinus Phase 1: nebulization to the 
lungs 
Phase 2: aerosolized 
Nasal and right lower lung 
lobe 
Clinical 
outcomes  
(# patients) 
Phase 1: No significant 
effect on NPD 
Phase 2: Limited change in 
NPD consistent with CFTR 
chloride channel activity 
(23/23) 
FEV1: n/a 
Phase 1: >30%↑ in 
pulmonary function (FEV1) 
(1/12) 
Phase 2: ↑FEV1 (20/37) 
NPD: n/a 
No significant change in NPD 
FEV1: n/a 
PCR-detectable 
gene expression 
(# patients) 
Phase 1: 6/10 
Phase 2: inconclusive  
17/37 5/25 
Noteable 
Adverse events 
(# patients) 
Phase 1: None 
Phase 2: 
- Acute peripheral 
vestibulopathy (1/23) 
-Sinusitis (78% of patients). 
Phase 1 (5/12): 
supraventricular 
tachycardia, pneumonia, 
pulmonary exacerbation, 
hemoptysis   
 
CF pulmonary exacerbation 
(9/25) 
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Table 4.6. Hemophilia Gene Therapy Clinical Trials 
ClinicalTrials.gov ID n/a NCT00515710 NCT00979238 
Published Results [275, 276, 289] [278] [50] 
Location Philadelphia, PA, USA Philadelphia, PA, USA London, UK 
Current Phase Unknown 1/2 1 
# Patients (range of 
ages at time of 
treatment) 
11 patients (23-67 yo) 7 patients (20-63 yo) 6 patients (29-64 yo) 
Follow-up range 2 years  12-40 months 6-16 months 
Vector/promoter AAV2/CMV AAV2/SERPINA1 (liver-
specific promoter) 
scAAV8-LP1-hFIXco (liver-
specific promoter/enhancer, 
mini codon-optimized FIX) 
Dose (vg/kg) 1.5x1012  
Cohort 1: 10-20 injection 
sites 
Cohort 2: 30-50 sites 
Cohort 3: 80-90 sites  
Cohort 1: 8x1010 -2x1012 Cohort 1: 2x1011 
Cohort 2: 6x1011 
Cohort 3: 2x1012 
Route of 
administration 
intramuscular intravenous intravenous 
Clinical outcomes (# 
patients) 
> 50% reduction in FIX 
prophylaxis sustained over 
100 days (2/11) 
 
- Therapeutic levels of FIX 
for 10 weeks (1/7)  
- No bleeding episodes or 
FIX prophylaxis for 10 weeks 
(1/7) 
 
- Therapeutic levels of FIX 
expression (6/6) 
 
- Discontinued prophylaxis 
(4/6) 
- Decreased frequency of 
prophylactic injections (2/6) 
Gene expression Long-term gene expression 
detected by qPCR, DNA in 
situ hybridization, and IHC 
(1/8) 
No long-term gene 
expression 
Persistent gene expression 
for 16 months (3/6) 
Noteable adverse 
events 
(# patients) 
Transient 
thrombocytopenia (1/8) 
Transient asymptomatic 
increases in transaminases 
(2/7) 
- Anemia (2/6) 
- Transient bradycardia (1/6) 
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APPENDIX A 
 
Statistics for Figure 2.3A.To assess differences between treatments (Nrf2-ETGE, Nrf2-WT, and 
the control conditions, both in the presence and absence of Keap), we applied a linear mixed 
effects regression model with luminescence as the outcome.  The model included fixed effects 
for repetition, the presence of Keap, treatment, and readout (Firefly vs. Renilla), and random 
well effects to account for correlation between outcomes from the same well in the same 
repetition.  Contrasts of interest were each tested at the two-sided 0.05 significance level with 
no adjustments for multiple comparisons. 
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